



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Effect of subanesthetic dose of esketamine induction on quality of recovery from general anesthesia: a propensity-score-matched retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-098558
Article Type:	Original research
Date Submitted by the Author:	27-Dec-2024
Complete List of Authors:	Wang, Dongdong; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Weng, Mengcao; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Chen, Kunwei; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Wu, Xiaojun; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Xiao, Yuanfang; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Wu, Yijie; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Qian, Minyue; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Lu, Zhongteng; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Fang, Xiangming; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Jin, Yue; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology; Zhejiang University School of Medicine Children's Hospital, Perioperative and Systems Medicine Laboratory
Keywords:	ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Adverse events < THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



*I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).*

*The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.*

*Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.*

**Effect of subanesthetic dose of esketamine induction on quality of recovery from general anesthesia: a propensity-score-matched retrospective study**

Dongdong Wang<sup>1</sup>, Mengcao Weng<sup>2</sup>, Kunwei Chen<sup>2</sup>, Xiaojun Wu<sup>1</sup>, Yuanfang Xiao<sup>1</sup>, Yijie Wu<sup>1</sup>, Minyue Qian<sup>2</sup>, Zhongteng Lu<sup>3</sup>, Xiangming Fang<sup>1\*</sup>, Yue Jin<sup>2, 3\*</sup>

1 Department of Anesthesiology and Intensive Care, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

2 Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

3 Perioperative and Systems Medicine Laboratory, Children's Hospital, Zhejiang

University School of Medicine, National Clinical Research Center for Child Health,

Hangzhou, China

**\*Correspondence:** Yue Jin, Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China, yue\_jin@zju.edu.cn; Xiangming Fang, Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China, xmfang@zju.edu.cn

**Running title:** Effect of esketamine on anesthetic recovery quality

**Keywords:** esketamine; general anesthesia with tracheal intubation; abdominal surgery; postoperative adverse event; subanesthetic dose

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23     **Abstract**

24     **Background:** Subanesthetic doses of esketamine may attenuate the opioid-induced  
25     cough reflex and prevent intraoperative hemodynamic fluctuations. However, studies  
26     on its effect on the quality of postoperative recovery are limited. This study aims to  
27     provide clinical evidence on the effect of using subanesthetic doses of esketamine on  
28     the quality of recovery in abdominal surgery patients.

29     **Methods:** Patients undergoing abdominal surgery with tracheal intubation between  
30     December 20, 2022, and April 30, 2023, were retrospectively reviewed. Patients were  
31     assigned to the esketamine or control group based on whether they received a  
32     subanesthetic dose of esketamine. Recovery time, quality of recovery, postoperative  
33     pain, and occurrence of other adverse events in the post-anesthesia care unit (PACU)  
34     were recorded. Propensity score matching (PSM) analysis was used to minimize  
35     confounding bias. The primary outcome was PACU recovery time, and secondary  
36     outcomes included postoperative pain and other adverse events.

37     **Results:** A total of 2,177 patients underwent abdominal surgery. After PSM, 598  
38     patients were included in each group. The use of subanesthetic doses of esketamine  
39     for induction of anesthesia significantly reduced the recovery time (20.00 vs. 23.00,  
40     p=0.001). There were no significant differences in PACU observation time after  
41     extubation. Total PACU time was shorter in the esketamine group than in the control  
42     group (62 vs. 66 minutes, p = 0.015). Compared to the control group, the esketamine  
43     group had significantly less severe postoperative pain immediately after extubation  
44     (0.33% vs. 2.01%, p = 0.007) and a lower incidence of respiratory depression (2.68%

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Ensignement Supérieur (ABES)

vs. 5.35%,  $p=0.027$ ). However, the esketamine group had a higher incidence of hypertension (9.53% vs. 6.35%,  $p=0.042$ ). There were no significant differences in other adverse events between the two groups.

**Conclusions:** The use of subanesthetic doses of esketamine for induction of anesthesia in patients undergoing abdominal surgery may shorten the recovery time and reduce the incidence of postoperative complications.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

52

53

54

55

56

57

58

59

**Strengths and limitations of this study**

This study represents a retrospective investigation of the effect of using subanesthetic doses of esketamine on the quality of recovery in abdominal surgery patients.

Using propensity score matching to ensure the baseline characteristics of patients.

As a single-center study focusing on the quality of recovery after anesthesia, the external validity of the results may be limited.

## Introduction

Approximately 313 million people worldwide undergo surgery each year, and general anesthesia with tracheal intubation is the most commonly used anesthetic technique.<sup>1 2</sup> Advances in medical technology have significantly reduced anesthesia-related mortality rates.<sup>3</sup> However, this approach can still lead to adverse events, such as intubation cough, intraoperative hemodynamic fluctuations, postoperative pain and postoperative cognitive dysfunction (POCD).<sup>4-7</sup> These reactions can prolong hospital stay and increase healthcare costs. Therefore, improving the efficacy and comfort of general anesthesia with tracheal intubation has become a pressing concern.

Esketamine is a modified version of the anesthetic ketamine that acts primarily by inhibiting the N-methyl-D-aspartate (NMDA) receptor, resulting in sedative and analgesic effects. Compared to ketamine, esketamine has a higher potency, stronger analgesic and sedative effects, and fewer side effects.<sup>8 9</sup> Previous research indicates that subanesthetic doses of esketamine, administered intravenously at 0.1-0.3 mg/kg or by infusion at 0.1-0.3 mg/kg·h can effectively reduce cough reflexes caused by opioid induction,<sup>10</sup> prevent intraoperative hemodynamic fluctuations,<sup>11</sup> and reduce the need for intraoperative propofol and opioid medications.<sup>12 13</sup> However, it remains unclear whether subanesthetic doses of esketamine in general anesthesia affect patient emergence and the incidence of postoperative delirium and agitation.<sup>14 15</sup>

This study retrospectively analyzes the effect of subanesthetic doses of esketamine used for intubation of general anesthesia on recovery quality, postoperative pain and

1

2

3

482adverse events in patients undergoing abdominal surgery. The objective is to provide

5

683clinical evidence regarding the effect of esketamine on recovery quality for abdominal

7

8

984surgery patients.

10

11

1285

13

1486**Methods**

15

16

1787**Study design and patient population**

18

1988This retrospective, single-center study was conducted at the First Affiliated

20

21

2289Hospital, Zhejiang University School of Medicine (Hangzhou, China), after receiving

23

24

2590approval by the Clinical Research Ethics Committee of the First Affiliated Hospital,

26

27

2891Zhejiang University School of Medicine (IIT20230403A). Informed consent from

29

3092patients was waived by the ethics committee. It was registered in the Chinese Clinical

31

32

3393Trial Registry ([www.chictr.org.cn](http://www.chictr.org.cn), ChiCTR2300072154, 05/06/2023). The medical

34

3594records used in this study were obtained from the medical database of the First

36

37

3895Affiliated Hospital, Zhejiang University School of Medicine.

39

4096From December 20, 2022 to April 30, 2023, patients who undergoing abdominal

41

42

4397surgery under general anesthesia with tracheal intubation were included in the study.

44

4598Inclusion criteria included an American Society of Anesthesiologists (ASA) physical

46

47

4899status of I to III, concurrent routine induction (sufentanil) with or without a

49

50100subanesthetic dose of esketamine for general anesthesia. Exclusion criteria were age

51

52

53101<18 years or > 80 years, hepatic or renal dysfunction, severe pulmonary disease,

54

55

56102severe cardiac dysfunction (New York Heart Association [NYHA] Classification 3-4),

57

58103central nervous system disorders, psychiatric disorders, severe preoperative anemia,

59

60

intraoperative bleeding  $\geq 500$  ml or intraoperative hemodynamic fluctuations, duration of surgery  $> 240$  min, postoperative intensive care unit (ICU) admission, and patients not transferred to the PACU after surgery.

### Anesthetic procedure

All patients were routinely fasted, anesthesia induction and management. On admission to the operating room, patients were monitored with electrocardiogram (ECG), non-invasive upper arm blood pressure, pulse oxygen saturation ( $SpO_2$ ), respiratory rate, partial pressure of end-tidal carbon dioxide ( $PetCO_2$ ), body temperature, and bispectral index (BIS). Invasive continuous arterial pressure monitoring and central venous pressure monitoring were performed as needed.

Patients in the control group received with midazolam (0.04 mg/kg), propofol (1.0-2.0 mg/kg), rocuronium (0.6 mg/kg), and sufentanil (0.3-0.5  $\mu$ g/kg). The esketamine group receives subanesthetic doses of esketamine (0.2 mg/kg) in addition to the above induction agents. During surgery, 0.8-1.5 minimum alveolar concentration (MAC) sevoflurane, 4-6 mg/kg·h propofol, and 0.1-0.3  $\mu$ g/kg·min remifentanyl were maintained. After surgery, 5 mg tropisetron and 50 mg ketorolac were administered intravenously. Postoperative analgesia was achieved with 0.375% ropivacaine for nerve block (transversus abdominis plane block, TAP) or local wound infiltration anesthesia.

Patients were transferred to the PACU after surgery, and endotracheal tubes were removed as soon as certain criteria were met (patients were awake, RR  $> 10$  breaths

per minute and tidal volume > 5 ml/kg). Inadequate muscle strength was treated with 0.04 mg/kg neostigmine and 0.02 mg/kg atropine intravenously. Supplemental oxygen at a rate of 2L/min was administered via nasal catheter after extubation. Pain was assessed using the Numeric Rating Scale (NRS) immediately, 15 minutes and 30 minutes after extubation. Hydromorphone (0.01mg/kg) was administered for pain relief if the NRS score exceeded 4 points. A jaw thrust or positive pressure ventilation with a face mask was used to treat respiratory depression. For dysphoria or delirium, propofol 0.5 mg/kg was used for sedation. If hypertension is diagnosed, intravenous amlodipine 5 mg is recommended. If hypotension occurs, ephedrine 6 mg should be administered. If shivering occurs, intravenous tramadol 50 mg is recommended. Discharge from the PACU was assessed using the modified Aldrete score, with a score of  $\geq 9$  indicating readiness for discharge.<sup>16 17</sup>

**Data collection**

Demographic and perioperative data were collected from the clinical information system (Seenew, Hangzhou, China) and institutional electronic Anesthesia Data Sysytem (Medical System, Suzhou, China), including: 1) preoperative data: gender, age, body mass index (BMI), medical history, and ASA classification; 2) intraoperative data: type of surgery, surgery duration, anesthesia duration, intraoperative blood loss, and use of the patient-controlled analgesia (PCA); 3) PACU data: heart rate, blood pressure, oxygen saturation, anesthesia recovery time, PACU observation time, the total PACU time, postoperative pain (NRS score), analgesic use,

incidence of hypertension, hypotension, and medication use. Additionally, the modified Aldrete score, respiratory depression, delirium and agitation, nausea/vomiting, shivering, and other PACU adverse events (e.g., reintubation) were recorded.

### **Primary outcome**

The primary outcome was anesthesia recovery time (T1), defined as the time from cessation of anesthetic drugs to extubation.

### **Secondary outcome**

Secondary outcomes included postoperative pain immediately after extubation, at 15 minutes, and at 30 minutes, and analgesic use. The modified Aldrete score at PACU discharge and the incidence of PACU adverse events including respiratory depression, hypertension, hypotension, delirium, agitation, nausea/vomiting, shivering, reintubation, and use of symptomatic treatment were recorded.

Respiratory depression was defined as respiratory rate falling below 8 breaths per minute or  $\text{SpO}_2 < 90\%$  for more than 1 minute.<sup>18 19</sup> In addition, the comparison of PACU observation time (T2), defined as the time from extubation to PACU discharge, total PACU time (T3), and PACU discharge delay rate, defined as the percentage of patients with a PACU time greater than 120 minutes, were analyzed.

### **Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Statistical analysis**

Sample size was calculated using PASS statistical software (NCSS LLC, Kaysville, USA). This is a retrospective case-control study, based on the previous results of the average anesthesia recovery time for both groups, with a two-tailed test,  $\alpha$  set at 0.05, power set at 90%, and 1:1 Sample ratio, a minimum sample size of 361 participants per group was required.

Propensity score matching (PSM) analysis was performed using R Project for Statistical Computing (Version 4.2.3, Lucent Technologies, Reston, USA) and the matchIt package to reduce differences between the two groups based on the esketamine administration to minimize confounding factors. Nearest-neighbor matching method was used in a 1:1 ratio, with a caliper value of 0.05. Matching variables included age, gender, BMI, medical history, ASA physical status classification, surgical category, surgery duration, anesthesia duration, intraoperative blood loss, and PCA use. Multiple linear regression analysis was used to complete the matching process.

All quantitative data were assessed for normality using the Shapiro-Wilk test. Normally distributed continuous data were presented as mean (standard deviation), and differences between groups were analyzed using t-tests or analysis of variance (ANOVA). Skewed data were presented as median (25<sup>th</sup>-75<sup>th</sup> percentile) and were

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

analyzed using the nonparametric Mann-Whitney U test. Categorical data were analyzed using the chi-squared test or Fisher's exact test. Ordinal data were analyzed using the Wilcoxon rank-sum test. All statistical analyses were performed with the SPSS software 22.0 (IBM corp., NY, USA). Statistical significance was defined as a P value  $< 0.05$ .

## Results

### Demographic and patient characteristics

A total of 2,177 patients with ASA physical status of I to III under sufentanil anesthesia underwent abdominal surgery, including hepatobiliary, gastrointestinal, and colorectal surgery, at the First Affiliated Hospital, Zhejiang University School of Medicine. Based on the inclusion and exclusion criteria, a final of 1,718 patients were enrolled, with 633 patients in the esketamine group and 1,085 patients in the control group. PSM successfully matched 598 patients in each group, achieving the required sample size (Figure 1). The use of PSM ensured that the baseline characteristics were similar between the two groups, as indicated by absolute standardized mean differences (SMD) of less than 0.1 for all variables (Figure 2). The distributions of the propensity scores and the SMD of the covariates were well balanced after PSM adjustment (Figure 3).

Patient characteristics in the esketamine group and control groups before and after PSM are shown in Table 1. After PSM, there were no significant differences in the patient characteristics in gender, age, BMI, medical history, ASA classification, type

of surgery, surgery duration, anesthesia duration, intraoperative blood loss, and use of the PCA between the two groups ( $P > 0.05$ ).

**Primary outcome**

The results showed that the anesthetic recovery time (T1) in the esketamine group was 20 (11, 32) minutes, while the T1 in the control group was 23 (13, 37) minutes ( $P = 0.001$ ), indicating that patients induced with subanesthetic doses of esketamine had faster recovery in the PACU (Table 2).

**Secondary outcome**

The number of patients with severe postoperative pain immediately after extubation was significantly higher in the control group (12, 2.01%) than that in the esketamine groups (2, 0.33%) ( $p = 0.007$ ). In addition, the number of patients requiring additional hydromorphone for postoperative pain during PACU treatment was significantly higher in the control group (94, 15.72%) than in the esketamine group (70, 11.71%) ( $p = 0.044$ ). However, there were no statistically significant differences in the number of patients with postoperative pain between the two groups at 15 and 30 minutes after extubation, as shown in Table 3.

During the PACU period, the number of patients with respiratory depression in the control group was 32 (5.35%), significantly higher than the 16 (2.68%) cases in the esketamine group ( $p=0.027$ ). The esketamine group had a significantly higher rate of hypertension than the control group (9.53% vs. 6.35%,  $p=0.042$ ). There were no

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

significant differences in hypotension, delirium and agitation, nausea and vomiting, or shivering between the two groups. There were no emergencies requiring reintubation in either group. There were also no statistically significant differences in the modified Aldrete scores between the two groups when patients left the PACU (Table 4).

In addition, the total PACU time (T3) was also shorter in the esketamine group (62.00 vs. 66.00,  $p=0.015$ ). However, there was no significant difference in the PACU observation time (T2) between the two groups, with median times of 38 minutes in the control group and 37 minutes in the esketamine group ( $p = 0.738$ ). The number of patients with delayed discharge from the PACU was 30 (5.02%) in the esketamine group and 38 (6.35%) in the control group, respectively ( $p = 0.318$ ) (Table 2).

## Discussion

The results of the current study indicate that the use of subanesthetic doses of esketamine can effectively reduce the postoperative recovery time in the PACU for patients undergoing abdominal surgery. In addition, esketamine was found to reduce postoperative pain without increasing post-extubation side effects.

Previously, it was thought that the combining different mechanisms, such as esketamine with midazolam, propofol, or sevoflurane, could deepen the level of anesthesia and influence patient recovery.<sup>20 21</sup> However, recent studies have shown that esketamine not only increases the depth of anesthesia but also accelerates recovery from anesthesia.<sup>22</sup> Animal studies have shown that ketamine, the parent compound of esketamine, can shorten the peak activation time of the glutamatergic

neurons, particularly those in the paraventricular thalamus (PVT), thereby reducing anesthetic recovery time. Clinical studies have also shown that patients who received subanesthetic doses of esketamine intraoperatively had faster and better recovery of postoperative respiratory rate and tidal volume.<sup>23</sup> The current study supports these findings and suggests that the use of subanesthetic doses of esketamine may accelerate patient recovery.

This research shows that subanesthetic doses of esketamine are effective in relieving immediate post-extubation pain after extubation. Animal studies have suggested that the combining of NMDA receptor antagonists with opioids may result in synergistic or additive analgesic effects.<sup>24</sup> Numerous clinical studies have supported this concept by demonstrating that administration of 0.15-0.5 mg/kg of esketamine reduces intraoperative opioid consumption and improves postoperative pain management.<sup>12 13 25 26</sup> Consistent with these findings, the present study shows similar results. The subgroup that receiving subanesthetic doses of esketamine reported significantly lower pain levels immediately after extubation. While there was no significant difference in pain scores between the two groups at 15 and 30 minutes post-extubation, the PACU observation period showed a significant reduction in the number of patients in the esketamine group requiring additional analgesics for postoperative pain relief compared to the control group, indicating the beneficial effect of subanesthetic doses of esketamine on overall postoperative pain relief. The major metabolite of esketamine is S-norketamine, which has approximately one-third the analgesic potency of esketamine and a longer elimination half-life. This may

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

280 explain the prolonged analgesic effect of esketamine in the PACU.<sup>23</sup>

281 The results of this study indicate that the incidence of respiratory depression was  
282 significantly lower in the esketamine group than that in the control group. Respiratory  
283 depression is a common adverse event in the PACU, with an incidence rate of  
284 approximately 5%,<sup>18</sup> which is similar to the incidence observed in the control group of  
285 this study. Causes of respiratory depression during the anesthetic recovery period  
286 include the use of opioids, residual effects of muscle relaxants, and the incomplete  
287 recovery of the respiratory system after surgery. It's worth noting that approximately  
288 20% of cases of respiratory depression are associated with the use of opioid  
289 medications.<sup>27</sup> Elevated carbon dioxide (CO<sub>2</sub>) levels can stimulate central  
290 chemoreceptors, leading to an increase in respiratory drive. However, the use of  
291 opioid medications attenuates this response.<sup>28</sup> Both animal and clinical studies have  
292 shown that ketamine can enhance CO<sub>2</sub> sensitivity and provide moderate protection  
293 against respiratory depression and bronchoconstriction.<sup>29 30</sup> Research by Jonkman *et*  
294 *al.* also suggests that low-dose esketamine may counteract the respiratory depressant  
295 effects of opioid drugs.<sup>31</sup> This suggests that the use of subanesthetic doses of  
296 esketamine to induce anesthesia may not only reduce opioid consumption but also  
297 stabilize respiration, thereby reducing the likelihood of fatal events.

298 The most common adverse events associated with esketamine primarily are  
299 psychological symptoms such as delirium, agitation, nightmares, and dissociative  
300 phenomena, which often follow a dose-dependent pattern.<sup>32 33</sup> Bornemann-Cimenti H  
301 *et al.* have confirmed that subanesthetic doses can reduce the incidence of

psychological symptoms associated with esketamine.<sup>34</sup> Our study supports this view and shows that subanesthetic doses of esketamine do not increase the incidence of delirium or agitation. In addition, there is no effect on the incidence of nausea and vomiting. The sympathomimetic effects of esketamine, which manifest as increased blood pressure and heart rate.<sup>11 35</sup> The incidence of hypertension was higher in the esketamine group than in the control group. This may be due to the increased blood pressure induced by esketamine.

The primary goal of the PACU is to improve turnover efficiency between surgical procedures and to increase patient satisfaction. Factors such as delirium, agitation, and postoperative pain can prolong the PACU stay.<sup>36</sup> However, the current study shows that the use of a subanesthetic dose of esketamine doesn't increase the incidence of these complications. Furthermore, the total PACU time for the esketamine group is shorter than that of the control group, suggesting that the use of esketamine may improve the efficiency of the PACU.

This study has several limitations to this study. First, it is a single-center, retrospective study. Second, the study dose of esketamine is subanesthetic, and the study did not investigate potential problems associated with other doses. Finally, this study focuses exclusively on patients undergoing abdominal surgery and does not include other types of surgery. Therefore, further research should include large, multicenter, prospective studies to fully address these limitations.

**Conclusions**

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Subanesthetic doses of esketamine have been shown to be effective in reducing the recovery time in patients undergoing abdominal surgery under general endotracheal anesthesia, without compromising the overall quality of recovery. In addition, the use of subanesthetic doses of esketamine has the potential to reduce the incidence of severe postoperative pain, thereby reducing the need for analgesia in the PACU. This approach also helps to reduce the incidence of respiratory depression, resulting in a shorter overall PACU time, and ultimately contributing to the overall recovery process for patients.

### **Funding**

This study was supported by National Natural Science Foundation of China (82372159 and 82230074).

### **Ethics statement**

The study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (IIT20230403A), and registered in the Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR2300072154).

### **Author contribution**

Dongdong Wang and Yue Jin contributed to the study design and drafting of the paper. Mengcao Weng, Kunwei Chen, Xiaojun Wu, Yuanfang Xiao, Yijie Wu Minyue Qian and Zhongteng Lu contributed to data acquisition. Dongdong Wang contributed to data analysis. All authors approved the version to be submitted.

### **Data availability statement**

Data will be made available on request.

**Conflict of interest**

All authors declare no conflicts of interest.

**References**

1. Ng-Kamstra JS, Nepogodiev D, Lawani I, et al. Perioperative mortality as a meaningful indicator: Challenges and solutions for measurement, interpretation, and health system improvement. *Anaesth Crit Care Pain Med* 2020;39(5):673-81. doi: 10.1016/j.accpm.2019.11.005

2. Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. *N Engl J Med* 2010;363(27):2638-50. doi: 10.1056/NEJMra0808281

3. Bainbridge D, Martin J, Arango M, et al. Perioperative and anaesthetic-related mortality in developed and developing countries: a systematic review and meta-analysis. *Lancet* 2012;380(9847):1075-81. doi: 10.1016/S0140-6736(12)60990-8

4. Shuying L, Ping L, Juan N, et al. Different interventions in preventing opioid-induced cough: a meta-analysis. *J Clin Anesth* 2016;34:440-7. doi: 10.1016/j.jclinane.2016.05.034

5. Hirsch J, DePalma G, Tsai TT, et al. Impact of intraoperative hypotension and blood pressure fluctuations on early postoperative delirium after non-cardiac surgery. *Br J Anaesth* 2015;115(3):418-26. doi: 10.1093/bja/aeu458

6. Popping DM, Zahn PK, Van Aken HK, et al. Effectiveness and safety of postoperative pain management: a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision): a database analysis of prospectively raised data. *Br J Anaesth* 2008;101(6):832-40. doi: 10.1093/bja/aen300
7. Niu X, Zheng S, Li S, et al. Role of Different Doses of Ketamine in Postoperative Neurocognitive Function in Aged Mice Undergoing Partial Hepatectomy by Regulating the Bmal1/NMDA/NF-Kappab Axis. *Eur Surg Res* 2022;63(4):182-95. doi: 10.1159/000520210
8. Wang J, Huang J, Yang S, et al. Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. *Drug Des Devel Ther* 2019;13:4135-44. doi: 10.2147/DDDT.S224553 [published Online First: 2019/12/13]
9. Xu Y, He L, Liu S, et al. Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. *PLoS One* 2023;18(6):e0286590. doi: 10.1371/journal.pone.0286590
10. Guler G, Aksu R, Bicer C, et al. Comparison of the effects of ketamine or lidocaine on fentanyl-induced cough in patients undergoing surgery: A prospective, double-blind, randomized, placebo-controlled study. *Curr Ther Res Clin Exp* 2010;71(5):289-97. doi: 10.1016/j.curtheres.2010.10.004
11. Li J, Wang Z, Wang A, et al. Clinical effects of low-dose esketamine for

anaesthesia induction in the elderly: A randomized controlled trial. *J Clin Pharm Ther* 2022;47(6):759-66. doi: 10.1111/jcpt.13604

12. Wang P, Song M, Wang X, et al. Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial. *Br J Clin Pharmacol* 2023;89(8):2542-51. doi: 10.1111/bcp.15726

13. Min M, Du C, Chen X, et al. Effect of subanesthetic dose of esketamine on postoperative rehabilitation in elderly patients undergoing hip arthroplasty. *J Orthop Surg Res* 2023;18(1):268. doi: 10.1186/s13018-023-03728-2

14. Zhang C, He J, Shi Q, et al. Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial. *BMC Anesthesiol* 2022;22(1):138. doi: 10.1186/s12871-022-01662-0

15. Chen S, Yang JJ, Zhang Y, et al. Risk of esketamine anesthesia on the emergence delirium in preschool children after minor surgery: a prospective observational clinical study. *Eur Arch Psychiatry Clin Neurosci* 2023 doi: 10.1007/s00406-023-01611-z [published Online First: 2023/04/19]

16. Hawker RJ, McKillop A, Jacobs S. Postanesthesia Scoring Methods: An Integrative Review of the Literature. *J Perianesth Nurs* 2017;32(6):557-72. doi: 10.1016/j.jopan.2016.10.007

17. Abdullah HR, Chung F. Postoperative issues: discharge criteria. *Anesthesiol Clin* 2014;32(2):487-93. doi: 10.1016/j.anclin.2014.02.013

18. Laporta ML, Sprung J, Weingarten TN. Respiratory depression in the post-anesthesia care unit: Mayo Clinic experience. *Bosn J Basic Med Sci*

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

- 2021;21(2):221-28. doi: 10.17305/bjbms.2020.4816
19. Eberl S, Koers L, van Hooft J, et al. The effectiveness of a low-dose esketamine versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatography: A randomised controlled multicentre trial. *Eur J Anaesthesiol* 2020;37(5):394-401. doi: 10.1097/EJA.0000000000001134
20. Rosow CE. Anesthetic drug interaction: an overview. *J Clin Anesth* 1997;9(6 Suppl):27S-32S. doi: 10.1016/s0952-8180(97)00124-4
21. Hendrickx JF, Eger EI, 2nd, Sonner JM, et al. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. *Anesth Analg* 2008;107(2):494-506. doi: 10.1213/ane.0b013e31817b859e
22. Duan WY, Peng K, Qin HM, et al. Esketamine accelerates emergence from isoflurane general anaesthesia by activating the paraventricular thalamus glutamatergic neurones in mice. *Br J Anaesth* 2024;132(2):334-42. doi: 10.1016/j.bja.2023.10.038 [published Online First: 2023/12/04]
23. Yuan J, Chen S, Xie Y, et al. Intraoperative Intravenous Infusion of Esmketamine Has Opioid-Sparing Effect and Improves the Quality of Recovery in Patients Undergoing Thoracic Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Pain Physician* 2022;25(9):E1389-E97. [published Online First: 2023/01/07]
24. Gupta A, Devi LA, Gomes I. Potentiation of mu-opioid receptor-mediated signaling by ketamine. *J Neurochem* 2011;119(2):294-302. doi: 10.1111/j.1471-4159.2011.07361.x

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

25. Nielsen RV, Fomsgaard JS, Siegel H, et al. Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial. *Pain* 2017;158(3):463-70. doi: 10.1097/j.pain.0000000000000782

26. Lei Y, Liu H, Xia F, et al. Effects of Esketamine on Acute and Chronic Pain After Thoracoscopy Pulmonary Surgery Under General Anesthesia: A Multicenter-Pro prospective, Randomized, Double-Blind, and Controlled Trial. *Front Med (Lausanne)* 2021;8:693594. doi: 10.3389/fmed.2021.693594

27. Weingarten TN, Sprung J. Review of Postoperative Respiratory Depression: From Recovery Room to General Care Unit. *Anesthesiology* 2022;137(6):735-41. doi: 10.1097/ALN.0000000000004391

28. Ayad S, Khanna AK, Iqbal SU, et al. Characterisation and monitoring of postoperative respiratory depression: current approaches and future considerations. *Br J Anaesth* 2019;123(3):378-91. doi: 10.1016/j.bja.2019.05.044

29. De Oliveira GS, Jr., Fitzgerald PC, Hansen N, et al. The effect of ketamine on hypoventilation during deep sedation with midazolam and propofol: a randomised, double-blind, placebo-controlled trial. *Eur J Anaesthesiol* 2014;31(12):654-62. doi: 10.1097/EJA.0000000000000025

30. Eikermann M, Grosse-Sundrup M, Zaremba S, et al. Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. *Anesthesiology* 2012;116(1):35-46. doi:

- 10.1097/ALN.0b013e31823d010a
31. Jonkman K, van Rijnsoever E, Olofsen E, et al. Esketamine counters opioid-induced respiratory depression. *Br J Anaesth* 2018;120(5):1117-27. doi: 10.1016/j.bja.2018.02.021
32. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. *Pharmacol Rev* 2018;70(3):621-60. doi: 10.1124/pr.117.015198
33. Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. *J Psychopharmacol* 2021;35(2):109-23. doi: 10.1177/0269881120959644
34. Bornemann-Cimenti H, Wejbora M, Michaeli K, et al. The effects of minimal-dose versus low-dose S-ketamine on opioid consumption, hyperalgesia, and postoperative delirium: a triple-blinded, randomized, active- and placebo-controlled clinical trial. *Minerva Anesthesiol* 2016;82(10):1069-76.
35. Zhou N, Liang X, Gong J, et al. S-ketamine used during anesthesia induction increases the perfusion index and mean arterial pressure after induction: A randomized, double-blind, placebo-controlled trial. *Eur J Pharm Sci* 2022;179:106312. doi: 10.1016/j.ejps.2022.106312
36. Munk L, Andersen G, Moller AM. Post-anaesthetic emergence delirium in adults: incidence, predictors and consequences. *Acta Anaesthesiol Scand* 2016;60(8):1059-66. doi: 10.1111/aas.12717



**Figure legends**

**Figure 1.** Flowchart of patient selection.

**Figure 2.** Standardized mean differences of covariates after PSM.

**Figure 3.** Distributions of propensity scores after PSM.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

**Table 1.** Comparison between the esketamine and control groups before and after propensity-score matching

	Before PSM						After PSM					
	Total (n=1718)	Control Group (n=1085)	Esketamine Group (n=633)	Statistic	P	SMD	Total (n=1196)	Control Group (n=598)	Esketamine Group (n=598)	Statistic	P	SMD
Age (yr)	58.00 (45.00, 66.00)	57.00 (43.00, 66.00)	58.00 (49.00, 66.00)	Z=-1.783	0.075	0.106	58.00 (47.00, 66.00)	58.00 (47.00, 67.00)	58.00 (48.00, 65.00)	Z=-0.711	0.477	-0.038
Gender										$\chi^2=0.023$	0.954	
Male	777 (45.23)	495 (45.62)	282 (44.55)			-0.022	533 (44.57)	266 (44.48)	267 (44.65)			0.003
Female	941 (54.77)	590 (54.38)	351 (55.45)			0.022	663 (55.43)	332 (55.52)	331 (55.35)			-0.003
BMI	23.41 (21.23, 25.39)	23.39 (21.23, 25.40)	23.44 (21.23, 25.34)	Z=-0.179	0.858	-0.024	23.40 (21.19, 25.39)	23.37 (21.10, 25.40)	23.44 (21.24, 25.35)	Z=-0.173	0.862	-0.018
Chronic disease												
Hypertension				$\chi^2=0.087$	0.768					$\chi^2=0.023$	0.880	
No	1412 (82.19)	894 (82.40)	518 (81.83)			-0.015	982 (82.11)	492 (82.22)	490 (81.94)			-0.009
Yes	306 (17.81)	191 (17.60)	115 (18.17)			0.015	214 (17.89)	106 (17.77)	108 (18.06)			0.009
Diabetes				$\chi^2=0.788$	0.375					$\chi^2=1.559$	0.212	
No	1618 (94.18)	1026 (94.56)	592 (93.52)			-0.042	1128 (94.31)	569 (95.11)	559 (93.48)			-0.068
Yes	100 (5.82)	59 (5.44)	41 (6.48)			0.042	68 (5.69)	29 (4.85)	39 (6.52)			0.068
Coronary heart disease				$\chi^2=1.716$	0.190					$\chi^2=1.831$	0.176	
No	1690 (98.37)	1064	626 (98.89)			0.079	1176	585 (97.83)	591 (98.83)			0.093

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

blood loss (ml)	50.00)	(10.00,	(10.00,			(10.00,	(10.00,	(10.00,	
		50.00)	50.00)			50.00)	50.00)	50.00)	
PCA				$\chi^2=2.677$	0.102			$\chi^2=1.680$	0.195
Yes	1197 (69.67)	771 (71.06)	426 (67.30)		-0.080	807 (67.47)	393 (65.72)	14 (69.23)	0.076
No	521 (30.33)	314 (28.94)	207 (32.70)		0.080	389 (32.53)	205 (34.28)	84 (30.77)	-0.076

Data are presented as median (quartile) or n (%).

ASA: American Society of Anesthesiologists; BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCA: Patient controlled analgesia; PSM: propensity score matching; SMD: standardized mean differences

**Table 2.** Recovery time after surgery.

	Control Group	Esketamine Group	statistic	<i>P</i> value
	(n=598)	(n=598)		
T1 (min)	23.00 (13.00, 37.00)	20.00 (11.00, 32.00)	-3.256	0.001
T2 (min)	38.00 (31.00, 50.00)	37.00 (31.00, 50.00)	-0.334	0.738
T3 (min)	66.00 (51.00, 85.00)	62.00 (48.00, 82.00)	-2.425	0.015
Delayed PACU discharge	38 (6.35)	30 (5.02)	0.998	0.318

Data are presented as median (quartile) or n (%).

PACU: post-anesthesia care unit; T1: anesthesia recovery time; T2: PACU observation time; T3: The total PACU time.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

**Table 3.** Postoperative pain scores and analgesic requirements.

	Control Group (n=598)	Esketamine Group (n=598)	statistic	<i>P</i> value
Postoperative pain immediately after extubation			7.227	0.007
NRS: 1-3	586 (97.99)	596 (99.67)		
NRS: $\geq 4$	12 (2.01)	2 (0.33)		
Postoperative pain, 15 minutes after extubation			1.411	0.235
NRS: 1-3	524 (87.63)	537 (89.80)		
NRS: $\geq 4$	74 (12.37)	61 (10.20)		
Postoperative pain, 30 minutes after extubation			0.820	0.365
NRS: 1-3	585 (97.99)	590 (98.66)		
NRS: $\geq 4$	12 (2.01)	8 (1.34)		
Use of analgesic drugs	94 (15.72)	70 (11.71)	4.070	0.044


Data are presented as n (%).

NRS: Numeric Rating Scale

**Table 4. Postoperative adverse events and the modified Aldrete score**


	Control Group	Esketamine Group	statistic	<i>P</i> value
	(n=598)	(n=598)		
Respiratory depression	32 (5.35)	16 (2.68)	4.884	0.027
Hypotension	15 (2.51)	14 (2.34)	0.035	0.851
Hypertension	38 (6.35)	57 (9.53)	4.28	0.042
Delirium and agitation	88 (14.72)	91 (15.22)	0.059	0.808
Nausea and vomiting	24 (4.01)	27 (4.52)	0.184	0.668
Shivering	14 (2.3)	17 (2.8)	0.298	0.584
Reintubation	0	0	-	-
The modified Aldrete score			0.451	0.502
9 points	40 (6.69)	46 (7.69)		
10 points	558 (93.31)	552 (92.31)		

Data are presented as n (%).



214x169mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



Esketamine



# BMJ Open

## Effect of subanesthetic dose of esketamine induction on quality of recovery from general anaesthesia in abdominal surgery: a propensity-score-matched retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-098558.R1
Article Type:	Original research
Date Submitted by the Author:	22-Apr-2025
Complete List of Authors:	Wang, Dongdong; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Weng, Mengcao; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Chen, Kunwei; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Wu, Xiaojun; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Xiao, Yuanfang; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Wu, Yijie; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Qian, Minyue; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Lu, Zhongteng; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Fang, Xiangming; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Jin, Yue; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology; Zhejiang University School of Medicine Children's Hospital, Perioperative and Systems Medicine Laboratory
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Adverse events < THERAPEUTICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

---

**Effect of subanesthetic dose of esketamine induction on quality of recovery from general anaesthesia in abdominal surgery: a propensity-score-matched retrospective study**

Dongdong Wang<sup>1</sup>, Mengcao Weng<sup>2</sup>, Kunwei Chen<sup>2</sup>, Xiaojun Wu<sup>1</sup>, Yuanfang Xiao<sup>1</sup>, Yijie Wu<sup>1</sup>, Minyue Qian<sup>2</sup>, Zhongteng Lu<sup>3</sup>, Xiangming Fang<sup>1\*</sup>, Yue Jin<sup>2,3\*</sup>

1 Department of Anesthesiology and Intensive Care, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

2 Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

3 Perioperative and Systems Medicine Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

**\*Correspondence:** Yue Jin, Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China, yue\_jin@zju.edu.cn; Xiangming Fang, Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China, xmfang@zju.edu.cn

**Running title:** Effect of esketamine on anesthetic recovery quality

**Keywords:** esketamine; general anaesthesia with tracheal intubation; abdominal surgery; postoperative adverse event; subanesthetic dose

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

**Abstract**

**Objectives:** Subanesthetic doses of esketamine may attenuate the opioid-induced cough reflex and prevent intraoperative hemodynamic fluctuations. This study aims to evaluate the effect of subanesthetic doses of esketamine on the quality of recovery in abdominal surgery patients.

**Design:** Retrospective cohort study using propensity-score matching (PSM) methodology.

**Setting:** A tertiary academic hospital.

**Participants:** Patients who underwent abdominal surgery under general anaesthesia with tracheal intubation between 20 December, 2022, and 30 April, 2023, were retrospectively reviewed. Patients were assigned to the esketamine or control group based on whether they received a subanesthetic dose of esketamine.

**Primary and secondary outcome measures:** The primary outcome was extubation time (T1). Secondary outcomes included PACU observation time (T2), total PACU time (T3), postoperative pain at multiple time points, and adverse events including respiratory depression, hypertension, and others.

**Results:** A total of 2,177 patients underwent abdominal surgery. After PSM, 1196 patients were analysed, 598 in each group. Esketamine significantly reduced the extubation time compared to the control group (20.00 min vs. 23.00 min,  $p=0.001$ ). Total PACU time was shorter in the esketamine group than in the control group (62 vs. 66 minutes,  $p = 0.015$ ), although PACU observation time did not show a significant difference. Compared to the control group, the esketamine group had a lower

incidence of severe postoperative pain immediately after extubation (0.33% vs. 2.01%,  $p = 0.007$ ) and a respiratory depression (2.68% vs. 5.35%,  $p=0.027$ ), but a higher incidence of hypertension (9.53% vs. 6.35%,  $p=0.042$ ). There were no other significant differences in adverse events between the two groups.

**Conclusions:** The use of subanesthetic doses of esketamine for induction of anaesthesia in patients undergoing abdominal surgery may shorten the extubation time and reduce the incidence of postoperative complications.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

53     **Strengths and limitations of this study**

- 54     ● Propensity score matching (PSM) was used to minimise selection bias and to
- 55     balance baseline characteristics between the groups of patients with and without
- 56     esketamine.
- 57     ● A relatively large sample size from a real clinical setting was included, which
- 58     increasing the generalisability of the results.
- 59     ● As a single-centre retrospective study, the generalisability of the findings may be
- 60     limited.
- 61     ● Residual confounding from unmeasured variables may still be present, potentially
- 62     affecting the results of the propensity score analysis.
- 63     ● Sensitivity analysis was not performed, which may affect the robustness of the
- 64     findings regarding residual confounding.

65

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

## Introduction

Approximately 313 million people worldwide undergo surgery each year, and general anaesthesia with tracheal intubation is the most commonly used anesthetic technique.<sup>1 2</sup> Advances in medical technology have significantly reduced anaesthesia-related mortality rates.<sup>3</sup> However, this approach can still lead to adverse events, such as intubation cough, intraoperative hemodynamic fluctuations, postoperative pain and postoperative cognitive dysfunction (POCD).<sup>4-7</sup> These reactions can prolong hospital stay and increase healthcare costs. Therefore, improving the efficacy and comfort of general anaesthesia with tracheal intubation has become a pressing concern.

Esketamine is a modified version of the anesthetic ketamine that acts primarily by inhibiting the N-methyl-D-aspartate (NMDA) receptor, resulting in sedative and analgesic effects. Compared to ketamine, esketamine has a higher potency, stronger analgesic and sedative effects, and fewer side effects.<sup>8 9</sup> Previous research indicates that subanesthetic doses of esketamine, administered intravenously at 0.1-0.3 mg/kg or by infusion at 0.1-0.3 mg/kg·h can effectively reduce cough reflexes caused by opioid induction,<sup>10</sup> prevent intraoperative hemodynamic fluctuations,<sup>11</sup> and reduce the need for intraoperative propofol and opioid medications.<sup>12 13</sup> However, it remains unclear whether subanesthetic doses of esketamine in general anaesthesia affect patient emergence and the incidence of postoperative delirium and agitation.<sup>14 15</sup>

This study retrospectively analyzes the effect of subanesthetic doses of esketamine used for intubation of general anaesthesia on recovery quality, postoperative pain and

1

2

3

488adverse events in patients undergoing abdominal surgery. The objective is to provide

5

689clinical evidence regarding the effect of esketamine on recovery quality for abdominal

7

8

990surgery patients. Propensity score matching (PSM) was used to adjust pairs of patients

10

11

1291with and without esketamine for potential confounders.

13

14

1592

16

1793**Methods**

18

19

2094**Study design and patient population**

21

2295This retrospective, single-centre study was conducted at the First Affiliated

23

2496Hospital, Zhejiang University School of Medicine (Hangzhou, China). It was

25

26

2797registered in the Chinese Clinical Trial Registry ([www.chictr.org.cn](http://www.chictr.org.cn),

28

29

3098ChiCTR2300072154, 05/06/2023). The medical records used in this study were

31

32

3399obtained from the medical database of the First Affiliated Hospital, Zhejiang

34

35100University School of Medicine.

36

37

38101From December 20, 2022 to April 30, 2023, patients who had abdominal surgery

39

40102under general anaesthesia with tracheal intubation were included in the study.

41

42

43103Inclusion criteria included an American Society of Anesthesiologists (ASA) physical

44

45104status of I to III, concurrent routine induction (sufentanil) with or without a

46

47

48105subanesthetic dose of esketamine for general anaesthesia. Exclusion criteria were age

49

50

51106<18 years or > 80 years, hepatic or renal dysfunction, severe pulmonary disease,

52

53107severe cardiac dysfunction (New York Heart Association [NYHA] Classification 3-4),

54

55

56108central nervous system disorders, psychiatric disorders, severe preoperative anemia,

57

58109intraoperative bleeding  $\geq$  500 ml or severe intraoperative haemodynamic fluctuations

59

60

with markedly unstable vital signs caused by massive bleeding, duration of surgery > 240 min, postoperative intensive care unit (ICU) admission, and patients not transferred to the PACU after surgery.

### Anesthetic procedure

All patients underwent preoperative fasting. On admission to the operating room, patients were monitored with electrocardiogram (ECG), non-invasive upper arm blood pressure, pulse oxygen saturation (SpO<sub>2</sub>), respiratory rate, partial pressure of end-tidal carbon dioxide (PetCO<sub>2</sub>), body temperature, and bispectral index (BIS). Invasive continuous arterial pressure monitoring and central venous pressure monitoring were performed as needed.

Patients in the control group received with midazolam (0.04 mg/kg), propofol (1.0-2.0 mg/kg), rocuronium (0.6 mg/kg), and sufentanil (0.3-0.5 µg/kg). The esketamine group receives subanesthetic doses of esketamine (0.2 mg/kg) in addition to the above induction agents. During surgery, 0.8-1.5 minimum alveolar concentration (MAC) sevoflurane, 4-6 mg/kg·h propofol, and 0.1-0.3 µg/kg·min remifentanyl were maintained. After surgery, 5 mg tropisetron and 50 mg ketorolac were administered intravenously. Postoperative analgesia was achieved with 0.375% ropivacaine for nerve block (transversus abdominis plane block, TAP) or local wound infiltration anaesthesia.

Patients were transferred to the PACU after surgery, and endotracheal tubes were removed as soon as certain criteria were met (patients were awake, RR > 10 breaths

per minute and tidal volume > 5 ml/kg). Inadequate muscle strength was treated with 0.04 mg/kg neostigmine and 0.02 mg/kg atropine intravenously. Supplemental oxygen at a rate of 2L/min was administered via nasal catheter after extubation. Pain was assessed using the Numeric Rating Scale (NRS) immediately, 15 minutes and 30 minutes after extubation. Hydromorphone (0.01mg/kg) was administered for pain relief if the NRS score exceeded 4 points. A jaw thrust or positive pressure ventilation with a face mask was used to treat respiratory depression. For dysphoria or delirium, propofol 0.5 mg/kg was used for sedation. If hypertension is diagnosed, intravenous amlodipine 5 mg is recommended. If hypotension occurs, ephedrine 6 mg should be administered. If shivering occurs, intravenous tramadol 50 mg is recommended. Discharge from the PACU was assessed using the modified Aldrete score, with a score of  $\geq 9$  indicating readiness for discharge.<sup>16 17</sup>

**Data collection**

Demographic and perioperative data were collected from the clinical information system (Seenew, Hangzhou, China) and institutional electronic Anaesthesia Data Sysytem (Medical System, Suzhou, China), including: 1) preoperative data: gender, age, body mass index (BMI), medical history, and ASA classification; 2) intraoperative data: type of surgery, surgery duration, anaesthesia duration, intraoperative blood loss, and use of the patient-controlled analgesia (PCA); 3) PACU data: heart rate, blood pressure, oxygen saturation, extubation time, PACU observation time, the total PACU time, postoperative pain (NRS score), analgesic use,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

incidence of hypertension, hypotension, and medication use. Additionally, the modified Aldrete score, respiratory depression, delirium and agitation, nausea/vomiting, shivering, and other PACU adverse events (e.g., reintubation) were recorded.

### **Primary outcome**

The primary outcome was extubation time (T1), defined as the time from discontinuation of anaesthesia to extubation (minutes).

### **Secondary outcome**

Secondary outcomes included postoperative pain immediately after extubation, at 15 minutes, and at 30 minutes, and analgesic use. The modified Aldrete score at PACU discharge and the incidence of PACU adverse events including respiratory depression, hypertension, hypotension, delirium, agitation, nausea/vomiting, shivering, reintubation, and use of symptomatic treatment were recorded.

Respiratory depression was defined as respiratory rate falling below 8 breaths per minute or  $\text{SpO}_2 < 90\%$  for more than 1 minute.<sup>18 19</sup> In addition, the comparison of PACU observation time (T2), defined as the time from extubation to PACU discharge, total PACU time (T3), defined as the interval from PACU admission to discharge, and PACU discharge delay rate, defined as the percentage of patients with a PACU time greater than 120 minutes, were analyzed.

**Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Propensity score matching**

Propensity score matching (PSM) analysis was performed using R Project for Statistical Computing (Version 4.2.3, Lucent Technologies, Reston, USA) and the matchIt package to reduce differences between the two groups based on the esketamine administration to minimize confounding factors. It is generally accepted that a standardised mean difference (SMD) of less than 0.1 for all variables indicates a good fit. For binary variables, the SMD is the difference in event rates between the treatment and control groups divided by the pooled standard deviation, where the pooled p is the weighted average of the event rates in both groups. For multi-category variables, the variable is split into several binary dummy variables and the SMD is calculated separately for each dummy variable, taking the maximum absolute value. Nearest-neighbor matching method was used in a 1:1 ratio, with a caliper value of 0.05. Matching variables included age, gender, BMI, chronic disease, ASA physical status classification, surgical category, surgery duration, anaesthesia duration, intraoperative blood loss, and PCA use, as indicated by absolute standardized mean differences (SMD) of less than 0.1 for all variables. Multiple linear regression analysis was used to complete the matching process.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

## Statistical analysis

Sample size was calculated using PASS statistical software (NCSS LLC, Kaysville, USA). This was a retrospective case-control study. Based on our previous results, the mean extubation time for both groups were  $19.00 \pm 11.52$  min and  $22.15 \pm 14.42$  min, respectively. A two-tailed test with  $\alpha$  set at 0.05, 90% power and a sample size of 1:1 indicated that a minimum sample size of 361 participants per group was required. As PSM will be used for case selection, we included a larger sample size to ensure that the final number after PSM met the required threshold.

All quantitative data were assessed for normality using the Shapiro-Wilk test. Normally distributed continuous data were presented as mean (standard deviation), and differences between groups were analyzed using t-tests or analysis of variance (ANOVA). Skewed data were presented as median (25<sup>th</sup>-75<sup>th</sup> percentile) and were analyzed using the nonparametric Mann-Whitney U test. Categorical data were analyzed using the chi-squared test or Fisher's exact test. Ordinal data were analyzed using the Wilcoxon rank-sum test. All statistical analyses were performed with the SPSS software 22.0 (IBM corp., NY, USA). Statistical significance was defined as a P value  $< 0.05$ .

## Results

### Demographic and patient characteristics

A total of 2,177 patients with ASA physical status of I to III under sufentanil anaesthesia underwent abdominal surgery, including hepatobiliary, gastrointestinal,

and colorectal surgery, at the First Affiliated Hospital, Zhejiang University School of Medicine. Based on the inclusion and exclusion criteria, a final of 1,718 patients were enrolled, with 633 patients in the esketamine group and 1,085 patients in the control group. PSM successfully matched 598 patients in each group, achieving the required sample size (Figure 1). The use of PSM ensured that the baseline characteristics were similar between the two groups (Figure 2). The distributions of the propensity scores and the SMD of the covariates were well balanced after PSM adjustment (Figure 3).

Patient characteristics in the esketamine group and control groups before and after PSM are shown in Table 1. After PSM, there were no significant differences ( $P > 0.05$ ) in the patient characteristics in gender, age, BMI, medical history, ASA classification, type of surgery, surgery duration, anaesthesia duration, intraoperative blood loss, and use of the PCA between the two groups.

**Primary outcome**

The results showed that the extubation time (T1) in the esketamine group was 20 (11, 32) minutes, while the T1 in the control group was 23 (13, 37) minutes ( $P = 0.001$ ), indicating that patients induced with subanesthetic doses of esketamine had faster recovery in the PACU (Table 2). Multiple linear regression suggests that ketamine is an independent protective factor for extubation time (Supplementary Table 1).

**Secondary outcome**

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

The number of patients with severe postoperative pain immediately after extubation was significantly higher in the control group (12, 2.01%) than that in the esketamine groups (2, 0.33%) ( $p = 0.007$ ). In addition, the number of patients requiring additional hydromorphone for postoperative pain during PACU treatment was significantly higher in the control group (94, 15.72%) than in the esketamine group (70, 11.71%) ( $p = 0.044$ ). However, there were no statistically significant differences in the number of patients with postoperative pain between the two groups at 15 and 30 minutes after extubation, as shown in Table 3.

During the PACU period, the number of patients with respiratory depression in the control group was 32 (5.35%), significantly higher than the 16 (2.68%) cases in the esketamine group ( $p=0.027$ ). The esketamine group had a significantly higher rate of hypertension than the control group (9.53% vs. 6.35%,  $p=0.042$ ). There were no significant differences in hypotension, delirium and agitation, nausea and vomiting, or shivering between the two groups. There were no emergencies requiring reintubation in either group. There were also no statistically significant differences in the modified Aldrete scores between the two groups when patients left the PACU (Table 4).

In addition, the total PACU time (T3) was also shorter in the esketamine group (62.00 vs. 66.00,  $p=0.015$ ). However, there was no significant difference in the PACU observation time (T2) between the two groups, with median times of 38 minutes in the control group and 37 minutes in the esketamine group ( $p = 0.738$ ). The number of patients with delayed discharge from the PACU was 30 (5.02%) in the esketamine group and 38 (6.35%) in the control group, respectively ( $p = 0.318$ ) (Table 2).

**Discussion**

The results of the current study indicate that the use of subanesthetic doses of esketamine can effectively reduce the postoperative extubation time in the PACU for patients undergoing abdominal surgery. In addition, esketamine was found to reduce postoperative pain without increasing post-extubation side effects.

Previously, it was thought that the combining different mechanisms, such as esketamine with midazolam, propofol, or sevoflurane, could deepen the level of anaesthesia and influence patient recovery.<sup>20 21</sup> However, recent studies have shown that esketamine not only increases the depth of anaesthesia but also accelerates recovery from anaesthesia.<sup>22</sup> Animal studies have shown that ketamine, the parent compound of esketamine, can shorten the peak activation time of the glutamatergic neurons, particularly those in the paraventricular thalamus (PVT), thereby reducing extubation time. Clinical studies have also shown that patients who received subanesthetic doses of esketamine intraoperatively had faster and better recovery of postoperative respiratory rate and tidal volume.<sup>23</sup> The current study supports these findings and suggests that the use of subanesthetic doses of esketamine may accelerate patient recovery.

This research shows that subanesthetic doses of esketamine are effective in relieving immediate post-extubation pain after extubation. Animal studies have suggested that the combining of NMDA receptor antagonists with opioids may result in synergistic or additive analgesic effects.<sup>24</sup> Numerous clinical studies have

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

supported this concept by demonstrating that administration of 0.15-0.5 mg/kg of esketamine reduces intraoperative opioid consumption and improves postoperative pain management.<sup>12 13 25 26</sup> Consistent with these findings, the present study shows similar results. The subgroup that receiving subanesthetic doses of esketamine reported significantly lower pain levels immediately after extubation. While there was no significant difference in pain scores between the two groups at 15 and 30 minutes post-extubation, the PACU observation period showed a significant reduction in the number of patients in the esketamine group requiring additional analgesics for postoperative pain relief compared to the control group, indicating the beneficial effect of subanesthetic doses of esketamine on overall postoperative pain relief. The major metabolite of esketamine is S-norketamine, which has approximately one-third the analgesic potency of esketamine and a longer elimination half-life. This may explain the prolonged analgesic effect of esketamine in the PACU.<sup>23</sup>

The results of this study indicate that the incidence of respiratory depression was significantly lower in the esketamine group than that in the control group. Respiratory depression is a common adverse event in the PACU, with an incidence rate of approximately 5%,<sup>18</sup> which is similar to the incidence observed in the control group of this study. Causes of respiratory depression during the anesthetic recovery period include the use of opioids, residual effects of muscle relaxants, and the incomplete recovery of the respiratory system after surgery. It's worth noting that approximately 20% of cases of respiratory depression are associated with the use of opioid medications.<sup>27</sup> Elevated carbon dioxide (CO<sub>2</sub>) levels can stimulate central

chemoreceptors, leading to an increase in respiratory drive. However, the use of opioid medications attenuates this response.<sup>28</sup> Both animal and clinical studies have shown that ketamine can enhance CO<sub>2</sub> sensitivity and provide moderate protection against respiratory depression and bronchoconstriction.<sup>29 30</sup> Research by Jonkman *et al.* also suggests that low-dose esketamine may counteract the respiratory depressant effects of opioid drugs.<sup>31</sup> This suggests that the use of subanesthetic doses of esketamine to induce anaesthesia may not only reduce opioid consumption but also stabilize respiration, thereby reducing the likelihood of fatal events.

The most common adverse events associated with esketamine primarily are psychological symptoms such as delirium, agitation, nightmares, and dissociative phenomena, which often follow a dose-dependent pattern.<sup>32 33</sup> Bornemann-Cimenti H *et al.* have confirmed that subanesthetic doses can reduce the incidence of psychological symptoms associated with esketamine.<sup>34</sup> Our study supports this view and shows that subanesthetic doses of esketamine do not increase the incidence of delirium or agitation. In addition, there is no effect on the incidence of nausea and vomiting. The sympathomimetic effects of esketamine, which manifest as increased blood pressure and heart rate.<sup>11 35</sup> The incidence of hypertension was higher in the esketamine group than in the control group. This may be due to the increased blood pressure induced by esketamine.

The primary goal of the PACU is to improve turnover efficiency between surgical procedures and to increase patient satisfaction. Factors such as delirium, agitation, and postoperative pain can prolong the PACU stay.<sup>36</sup> However, the current study shows

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

that the use of a subanesthetic dose of esketamine doesn't increase the incidence of these complications. Furthermore, the total PACU time for the esketamine group is shorter than that of the control group, suggesting that the use of esketamine may improve the efficiency of the PACU.

There are several limitations to this study. First, it is a single-centre, retrospective study, which may limit the generalisability of the findings. Although the two groups were matched on several demographic factors, there remains the potential for residual confounding due to unmeasured variables affecting the propensity score analysis. In addition, the lack of sensitivity analysis may affect the robustness of the results. Second, the dose of esketamine is subanesthetic, and the study did not investigate potential problems associated with other doses. Finally, this study focuses exclusively on patients undergoing abdominal surgery and does not include other types of surgery. Therefore, further research should include large, multicentre, prospective studies to fully address these limitations.

## Conclusions

Subanesthetic doses of esketamine have been shown to be effective in reducing the extubation time in patients undergoing abdominal surgery under general endotracheal anaesthesia, without compromising the overall quality of recovery. In addition, the use of subanesthetic doses of esketamine has the potential to reduce the incidence of severe postoperative pain, thereby reducing the need for analgesia in the PACU. This approach also helps to reduce the incidence of respiratory depression, resulting in a

shorter overall PACU time, and ultimately contributing to the overall recovery process for patients.

**Contributions** DW, XF and YJ contributed to the study design. MW, KC, XW, YX, YW, MQ and ZL contributed to data acquisition. DW contributed to data analysis and drafting of the paper. XF and YJ contributed to manuscript revision. YJ contributed to final approval of the version. All authors read and approved the final version. YJ is the guarantor.

**Funding** This work was supported by National Natural Science Foundation of China (82372159 and 82230074).

**Conflicting interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** The study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (IIT20230403A), and registered in the Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR2300072154).

**Data availability statement** Data will be made available on request. Further inquiries can be directed to the corresponding authors.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

---

## References

1. Ng-Kamstra JS, Nepogodiev D, Lawani I, et al. Perioperative mortality as a meaningful indicator: Challenges and solutions for measurement, interpretation, and health system improvement. *Anaesth Crit Care Pain Med* 2020;39:673-81.
2. Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. *N Engl J Med* 2010;363:2638-50.
3. Bainbridge D, Martin J, Arango M, et al. Perioperative and anaesthetic-related mortality in developed and developing countries: a systematic review and meta-analysis. *Lancet* 2012;380:1075-81.
4. Shuying L, Ping L, Juan N, et al. Different interventions in preventing opioid-induced cough: a meta-analysis. *J Clin Anesth* 2016;34:440-7.
5. Hirsch J, DePalma G, Tsai TT, et al. Impact of intraoperative hypotension and blood pressure fluctuations on early postoperative delirium after non-cardiac surgery. *Br J Anaesth* 2015;115:418-26.
6. Popping DM, Zahn PK, Van Aken HK, et al. Effectiveness and safety of postoperative pain management: a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision): a database analysis of prospectively raised data. *Br J Anaesth* 2008;101:832-40.
7. Niu X, Zheng S, Li S, et al. Role of Different Doses of Ketamine in Postoperative Neurocognitive Function in Aged Mice Undergoing Partial Hepatectomy by Regulating the Bmal1/NMDA/NF-Kappab Axis. *Eur Surg Res* 2022;63:182-95.
8. Wang J, Huang J, Yang S, et al. Pharmacokinetics and Safety of Esketamine in

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. *Drug Des Devel Ther* 2019;13:4135-44.

9. Xu Y, He L, Liu S, et al. Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. *PLoS One* 2023;18:e0286590.

10. Guler G, Aksu R, Bicer C, et al. Comparison of the effects of ketamine or lidocaine on fentanyl-induced cough in patients undergoing surgery: A prospective, double-blind, randomized, placebo-controlled study. *Curr Ther Res Clin Exp* 2010;71:289-97.

11. Li J, Wang Z, Wang A, et al. Clinical effects of low-dose esketamine for anaesthesia induction in the elderly: A randomized controlled trial. *J Clin Pharm Ther* 2022;47:759-66.

12. Wang P, Song M, Wang X, et al. Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial. *Br J Clin Pharmacol* 2023;89:2542-51.

13. Min M, Du C, Chen X, et al. Effect of subanesthetic dose of esketamine on postoperative rehabilitation in elderly patients undergoing hip arthroplasty. *J Orthop Surg Res* 2023;18:268.

14. Zhang C, He J, Shi Q, et al. Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial. *BMC Anesthesiol* 2022;22:138.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

- 
15. Chen S, Yang JJ, Zhang Y, et al. Risk of esketamine anesthesia on the emergence delirium in preschool children after minor surgery: a prospective observational clinical study. *Eur Arch Psychiatry Clin Neurosci* 2023;274:767-75.
16. Hawker RJ, McKillop A, Jacobs S. Postanesthesia Scoring Methods: An Integrative Review of the Literature. *J Perianesth Nurs* 2017;32:557-72.
17. Abdullah HR, Chung F. Postoperative issues: discharge criteria. *Anesthesiol Clin* 2014;32:487-93.
18. Laporta ML, Sprung J, Weingarten TN. Respiratory depression in the post-anesthesia care unit: Mayo Clinic experience. *Bosn J Basic Med Sci* 2021;21:221-28.
19. Eberl S, Koers L, van Hooft J, et al. The effectiveness of a low-dose esketamine versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatography: A randomised controlled multicentre trial. *Eur J Anaesthesiol* 2020;37:394-401.
20. Rosow CE. Anesthetic drug interaction: an overview. *J Clin Anesth* 1997;9:27S-32S.
21. Hendrickx JF, Eger EI, 2nd, Sonner JM, et al. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. *Anesth Analg* 2008;107:494-506.
22. Duan WY, Peng K, Qin HM, et al. Esketamine accelerates emergence from isoflurane general anaesthesia by activating the paraventricular thalamus glutamatergic neurones in mice. *Br J Anaesth* 2024;132:334-42.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23. Yuan J, Chen S, Xie Y, et al. Intraoperative Intravenous Infusion of Esmketamine Has Opioid-Sparing Effect and Improves the Quality of Recovery in Patients Undergoing Thoracic Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Pain Physician* 2022;25:E1389-E97.

24. Gupta A, Devi LA, Gomes I. Potentiation of mu-opioid receptor-mediated signaling by ketamine. *J Neurochem* 2011;119:294-302.

25. Nielsen RV, Fomsgaard JS, Siegel H, et al. Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial. *Pain* 2017;158:463-70.

26. Lei Y, Liu H, Xia F, et al. Effects of Esketamine on Acute and Chronic Pain After Thoracoscopy Pulmonary Surgery Under General Anesthesia: A Multicenter-Prospective, Randomized, Double-Blind, and Controlled Trial. *Front Med (Lausanne)* 2021;8:693594.

27. Weingarten TN, Sprung J. Review of Postoperative Respiratory Depression: From Recovery Room to General Care Unit. *Anesthesiology* 2022;137:735-41.

28. Ayad S, Khanna AK, Iqbal SU, et al. Characterisation and monitoring of postoperative respiratory depression: current approaches and future considerations. *Br J Anaesth* 2019;123:378-91.

29. De Oliveira GS, Jr., Fitzgerald PC, Hansen N, et al. The effect of ketamine on hypoventilation during deep sedation with midazolam and propofol: a randomised, double-blind, placebo-controlled trial. *Eur J Anaesthesiol*

- 2014;31:654-62.
30. Eikermann M, Grosse-Sundrup M, Zaremba S, et al. Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. *Anesthesiology* 2012;116:35-46.
31. Jonkman K, van Rijnsoever E, Olofsen E, et al. Esketamine counters opioid-induced respiratory depression. *Br J Anaesth* 2018;120:1117-27.
32. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. *Pharmacol Rev* 2018;70:621-60.
33. Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. *J Psychopharmacol* 2021;35:109-23.
34. Bornemann-Cimenti H, Wejbora M, Michaeli K, et al. The effects of minimal-dose versus low-dose S-ketamine on opioid consumption, hyperalgesia, and postoperative delirium: a triple-blinded, randomized, active- and placebo-controlled clinical trial. *Minerva Anesthesiol* 2016;82:1069-76.
35. Zhou N, Liang X, Gong J, et al. S-ketamine used during anesthesia induction increases the perfusion index and mean arterial pressure after induction: A randomized, double-blind, placebo-controlled trial. *Eur J Pharm Sci* 2022;179:106312.
36. Munk L, Andersen G, Moller AM. Post-anaesthetic emergence delirium in adults: incidence, predictors and consequences. *Acta Anaesthesiol Scand* 2016;60:1059-66.

**Figure legends**

**Figure 1.** Flowchart of patient selection.

**Figure 2.** Standardized mean differences of covariates after PSM.

**Figure 3.** Distributions of propensity scores after PSM.

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**Table 1.** Comparison between the esketamine and control groups before and after propensity-score matching

	Before PSM				After PSM			
	Total (n=1718)	Control Group (n=1085)	Esketamine Group (n=633)	P	Total (n=1196)	Control Group (n=598)	Esketamine Group (n=598)	P
Age (year), median (IQR)	58.00 (45.00, 66.00)	57.00 (43.00, 66.00)	58.00 (49.00, 66.00)	0.075	58.00 (47.00, 66.00)	58.00 (44.00, 67.00)	58.00 (48.00, 65.00)	0.477
Gender, n (%)								0.954
Male	777 (45.23)	495 (45.62)	282 (44.55)		533 (44.57)	266 (44.48)	267 (44.65)	
Female	941 (54.77)	590 (54.38)	351 (55.45)		663 (55.43)	332 (55.52)	331 (55.35)	
BMI, median (IQR)	23.41 (21.23, 25.39)	23.39 (21.23, 25.40)	23.44 (21.23, 25.34)	0.858	23.40 (21.19, 25.39)	23.39 (21.10, 25.40)	23.44 (21.24, 25.35)	0.862
Chronic disease								
Hypertension, n (%)				0.768				0.880
No	1412 (82.19)	894 (82.40)	518 (81.83)		982 (82.11)	492 (82.27)	490 (81.94)	
Yes	306 (17.81)	191 (17.60)	115 (18.17)		214 (17.89)	106 (17.73)	108 (18.06)	
Diabetes, n (%)				0.375				0.212
No	1618 (94.18)	1026 (94.56)	592 (93.52)		1128 (94.31)	569 (95.15)	559 (93.48)	
Yes	100 (5.82)	59 (5.44)	41 (6.48)		68 (5.69)	29 (4.85)	39 (6.52)	
Coronary heart disease, n (%)				0.190				0.176
No	1690 (98.37)	1064 (98.06)	626 (98.89)		1176 (98.33)	585 (97.83)	591 (98.83)	
Yes	28 (1.63)	21 (1.94)	7 (1.11)		20 (1.67)	13 (2.17)	7 (1.17)	
COPD, n (%)				0.151				0.615
No	1699 (98.89)	1076 (99.17)	623 (98.42)		1180 (98.66)	599 (98.83)	589 (98.49)	
Yes	19 (1.11)	9 (0.83)	10 (1.58)		16 (1.34)	7 (1.17)	9 (1.51)	
ASA physical status, n (%)								0.160
I	143 (8.32)	100 (9.22)	43 (6.79)		97 (8.11)	51 (9.53)	40 (6.69)	

II	1441 (83.88)	901 (83.04)	540 (85.31)		1016 (84.95)	503 (84.11)	513 (85.79)	
III	134 (7.8)	84 (7.74)	50 (7.90)		83 (6.94)	38 (6.35)	45 (7.53)	
Surgery type, n (%)				<0.001				0.515
Hepatobiliary surgery	919 (53.49)	622 (57.33)	297 (46.92)		597 (49.92)	225 (50.50)	295 (49.33)	
Gastrointestinal surgery	460 (26.78)	279 (25.71)	181 (28.59)		333 (27.84)	88 (26.42)	175 (29.26)	
Colorectal surgery	339 (19.73)	184 (16.96)	155 (24.49)		266 (22.24)	88 (23.08)	128 (21.40)	
Surgery duration (min) , median (IQR)	60.00 (38.00, 121.00)	55.00 (37.00, 112.00)	68.00 (41.00, 135.00)	<0.001	62.00 (39.00, 127.00)	58.25 (38.25, 117.75)	63.00 (40.00, 126.75)	0.757
Anaesthesia duration (min), median (IQR)	82.00 (58.00, 155.00)	79.00 (56.00, 147.00)	90.00 (60.00, 170.00)	<0.001	86.00 (58.00, 159.25)	75.50 (57.00, 111.00)	86.00 (59.00, 157.75)	0.858
Intraoperative blood loss (ml) , median (IQR)	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	0.004	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	0.580
PCA, n (%)				0.102				0.195
Yes	1197 (69.67)	771 (71.06)	426 (67.30)		807 (67.47)	393 (65.72)	414 (69.23)	
No	521 (30.33)	314 (28.94)	207 (32.70)		389 (32.53)	205 (34.28)	184 (30.77)	

ASA: American Society of Anesthesiologists; BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCA: Patient controlled analgesia; PSM: propensity score matching; SMD: standardized mean differences

**Table 2.** Recovery time after surgery.

	Control Group (n=598)	Esketamine Group (n=598)	<i>P</i> value
T1 (min), median (IQR)	23.00 (13.00, 37.00)	20.00 (11.00, 32.00)	0.001
T2 (min), median (IQR)	38.00 (31.00, 50.00)	37.00 (31.00, 50.00)	0.738
T3 (min), median (IQR)	66.00 (51.00, 85.00)	62.00 (48.00, 82.00)	0.015
Delayed PACU discharge, n (%)	38 (6.35)	30 (5.02)	0.318

PACU: post-anesthesia care unit; T1: extubation time; T2: PACU observation time;  
T3: The total PACU time.

**Table 3.** Postoperative pain scores and analgesic requirements.

	Control Group (n=598)	Esketamine Group (n=598)	<i>P</i> value
Postoperative pain immediately after extubation			0.007
NRS: 1-3	586 (97.99)	596 (99.67)	
NRS: ≥4	12 (2.01)	2 (0.33)	
Postoperative pain, 15 minutes after extubation			0.235
NRS: 1-3	524 (87.63)	537 (89.80)	
NRS: ≥4	74 (12.37)	61 (10.20)	
Postoperative pain, 30 minutes after extubation			0.365
NRS: ≥4	12 (2.01)	8 (1.34)	
Use of analgesic drugs	94 (15.72)	70 (11.71)	0.044

Data are presented as n (%).


NRS: Numeric Rating Scale

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).


**Table 4. Postoperative adverse events and the modified Aldrete score**

	Control Group (n=598)	Esketamine Group (n=598)	<i>P</i> value
Respiratory depression	32 (5.35)	16 (2.68)	0.027
Hypotension	15 (2.51)	14 (2.34)	0.851
Hypertension	38 (6.35)	57 (9.53)	0.042
Delirium and agitation	88 (14.72)	91 (15.22)	0.808
Nausea and vomiting	24 (4.01)	27 (4.52)	0.668
Shivering	14 (2.3)	17 (2.8)	0.584
Reintubation	0	0	-
The modified Aldrete score			0.502
9 points	40 (6.69)	46 (7.69)	
10 points	558 (93.31)	552 (92.31)	

Data are presented as n (%).




214x169mm (96 x 96 DPI)



Treatment ■ Control ■ Esketamine

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38



For peer review only - <http://bmjopen.bmj.com/submit/about/guidelines.xhtml>

BMJ Open: first published as 10.1136/bmjopen-2024-029000 on 30 May 2025. Downloaded from <http://bmjopen.bmj.com/> on June 8, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).  
All rights reserved. No reuse allowed without permission. See <http://bmjopen.bmj.com/submit/about/guidelines.xhtml> for uses related to text and data mining, AI training, and similar technologies.

## Supplementary data

Supplement Table 1. Results of multiple linear regression analysis

Variables	b	S.E	t	$\beta$ (95%CI)	P	m_b	m_S.E	m	a $\beta$ (95%CI)	aP
Age	0.27	0.04	7.09	0.27 (0.20 ~ 0.35)	<.001	0.20	0.04	5.23	0.20 (0.12 ~ 0.27)	<.001
Gender										
Male				0.00 (Reference)						
Female	1.38	1.12	1.23	1.38 (-0.82 ~ 3.58)	0.218					
BMI	-0.89	0.17	-5.34	-0.89 (-1.21 ~ -0.56)	<.001	-0.60	0.16	-3.8	-0.60 (-0.91 ~ -0.30)	<.001
Chronic disease										
Hypertension										
No				0.00 (Reference)						
Yes	0.20	1.46	0.14	0.20 (-2.65 ~ 3.06)	0.888					
Diabetes										
No				0.00 (Reference)						
Yes	-1.78	2.41	-0.74	-1.78 (-6.51 ~ 2.94)	0.459					
Coronary heart disease										
No				0.00 (Reference)						
Yes	3.28	4.35	0.75	3.28 (-5.25 ~ 11.81)	0.451					
COPD										
No				0.00 (Reference)					0.00 (Reference)	
Yes	11.59	4.85	2.39	11.59 (2.10 ~ 21.09)	0.017	5.42	4.48	1.21	5.42 (-3.36 ~ 14.20)	0.226
ASA physical status										
I				0.00 (Reference)						
II	3.82	2.05	1.86	3.82 (-0.20 ~ 7.83)	0.062					
III	3.34	2.88	1.16	3.34 (-2.31 ~ 8.99)	0.246					
Surgery type										
Hepatobiliary surgery				0.00 (Reference)					0.00 (Reference)	
Gastrointestinal surgery	-3.97	1.29	-3.08	-3.97 (-6.50 ~ -1.44)	0.002	-3.70	1.23	-3.00	-3.70 (-6.12 ~ -1.28)	0.003

Colorectal surgery	7.89	1.39	5.68	7.89 (5.17 ~ 10.61)	<.001	1.20	1.60	0.71	1.20 (-1.92 ~ 4.33)	0.451
Surgery duration (min)	0.09	0.01	9.58	0.09 (0.07 ~ 0.11)	<.001	0.05	0.07	0.81	0.05 (-0.08 ~ 0.18)	0.417
Anesthesia duration (min)	0.09	0.01	9.80	0.09 (0.07 ~ 0.10)	<.001	-0.05	0.06	-0.71	-0.05 (-0.17 ~ 0.07)	0.442
Intraoperative blood loss (ml)	0.10	0.01	10.50	0.10 (0.08 ~ 0.12)	<.001	0.06	0.01	5.37	0.06 (0.04 ~ 0.08)	<.001
Esketamine										
No				0.00 (Reference)					0.00 (Reference)	
Yes	-3.35	1.11	-3.01	-3.35 (-5.53 ~ -1.17)	0.003	-2.83	1.02	-2.71	-2.83 (-4.84 ~ -0.83)	0.006
PCA										
No				0.00 (Reference)					0.00 (Reference)	
Yes	12.55	1.13	11.06	12.55 (10.32 ~ 14.77)	<.001	6.04	1.67	3.62	6.04 (2.77 ~ 9.31)	<.001

ASA: American Society of Anesthesiologists; BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCA: Patient controlled analgesia; PSM: propensity score matching

# BMJ Open

## Effect of subanesthetic dose of esketamine induction on quality of recovery from general anaesthesia in abdominal surgery: a propensity-score-matched retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-098558.R2
Article Type:	Original research
Date Submitted by the Author:	30-Apr-2025
Complete List of Authors:	Wang, Dongdong; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Weng, Mengcao; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Chen, Kunwei; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Wu, Xiaojun; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Xiao, Yuanfang; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Wu, Yijie; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Qian, Minyue; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Lu, Zhongteng; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology Fang, Xiangming; Zhejiang University School of Medicine First Affiliated Hospital, Department of Anesthesiology and Intensive Care Jin, Yue; Zhejiang University School of Medicine Children's Hospital, Department of Anesthesiology; Zhejiang University School of Medicine Children's Hospital, Perioperative and Systems Medicine Laboratory
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Adverse events < THERAPEUTICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

---

**Effect of subanesthetic dose of esketamine induction on quality of recovery from general anaesthesia in abdominal surgery: a propensity-score-matched retrospective study**

Dongdong Wang<sup>1</sup>, Mengcao Weng<sup>2</sup>, Kunwei Chen<sup>2</sup>, Xiaojun Wu<sup>1</sup>, Yuanfang Xiao<sup>1</sup>, Yijie Wu<sup>1</sup>, Minyue Qian<sup>2</sup>, Zhongteng Lu<sup>3</sup>, Xiangming Fang<sup>1\*</sup>, Yue Jin<sup>2, 3\*</sup>

1 Department of Anesthesiology and Intensive Care, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

2 Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

3 Perioperative and Systems Medicine Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

**\*Correspondence:** Yue Jin, Department of Anesthesiology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China, yue\_jin@zju.edu.cn; Xiangming Fang, Department of Anesthesiology and Intensive Care, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China, xmfang@zju.edu.cn

**Running title:** Effect of esketamine on anesthetic recovery quality

**Keywords:** esketamine; general anaesthesia with tracheal intubation; abdominal surgery; postoperative adverse event; subanesthetic dose

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

**Abstract**

**Objectives:** Subanesthetic doses of esketamine may attenuate the opioid-induced cough reflex and prevent intraoperative hemodynamic fluctuations. This study aims to evaluate the effect of subanesthetic doses of esketamine on the quality of recovery in abdominal surgery patients.

**Design:** Retrospective cohort study using propensity-score matching (PSM) methodology.

**Setting:** A tertiary academic hospital.

**Participants:** Patients who underwent abdominal surgery under general anaesthesia with tracheal intubation between 20 December, 2022, and 30 April, 2023, were retrospectively reviewed. Patients were assigned to the esketamine or control group based on whether they received a subanesthetic dose of esketamine.

**Primary and secondary outcome measures:** The primary outcome was extubation time (T1). Secondary outcomes included PACU observation time (T2), total PACU time (T3), postoperative pain at multiple time points, and adverse events including respiratory depression, hypertension, and others.

**Results:** A total of 2,177 patients underwent abdominal surgery. After PSM, 1196 patients were analysed, 598 in each group. Esketamine significantly reduced the extubation time compared to the control group (20.00 min vs. 23.00 min,  $p=0.001$ ). Total PACU time was shorter in the esketamine group than in the control group (62 vs. 66 minutes,  $p = 0.015$ ), although PACU observation time did not show a significant difference. Compared to the control group, the esketamine group had a lower

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

incidence of severe postoperative pain immediately after extubation (0.33% vs. 2.01%,  $p = 0.007$ ) and a respiratory depression (2.68% vs. 5.35%,  $p=0.027$ ), but a higher incidence of hypertension (9.53% vs. 6.35%,  $p=0.042$ ). There were no other significant differences in adverse events between the two groups.

**Conclusions:** The use of subanesthetic doses of esketamine for induction of anaesthesia in patients undergoing abdominal surgery may shorten the extubation time and reduce the incidence of postoperative complications.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

53     **Strengths and limitations of this study**

- 54     ● Propensity score matching (PSM) was used to minimise selection bias and to
- 55         balance baseline characteristics between the groups of patients with and without
- 56         esketamine.
- 57     ● A relatively large sample size from a real clinical setting was included, which
- 58         increasing the generalisability of the results.
- 59     ● As a single-centre retrospective study, the generalisability of the findings may be
- 60         limited.
- 61     ● Residual confounding from unmeasured variables may still be present, potentially
- 62         affecting the results of the propensity score analysis.
- 63     ● Sensitivity analysis was not performed, which may affect the robustness of the
- 64         findings regarding residual confounding.

65

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

## Introduction

Approximately 313 million people worldwide undergo surgery each year, and general anaesthesia with tracheal intubation is the most commonly used anesthetic technique.<sup>1 2</sup> Advances in medical technology have significantly reduced anaesthesia-related mortality rates.<sup>3</sup> However, this approach can still lead to adverse events, such as intubation cough, intraoperative hemodynamic fluctuations, postoperative pain and postoperative cognitive dysfunction (POCD).<sup>4-7</sup> These reactions can prolong hospital stay and increase healthcare costs. Therefore, improving the efficacy and comfort of general anaesthesia with tracheal intubation has become a pressing concern.

Esketamine is a modified version of the anesthetic ketamine that acts primarily by inhibiting the N-methyl-D-aspartate (NMDA) receptor, resulting in sedative and analgesic effects. Compared to ketamine, esketamine has a higher potency, stronger analgesic and sedative effects, and fewer side effects.<sup>8 9</sup> Previous research indicates that subanesthetic doses of esketamine, administered intravenously at 0.1-0.3 mg/kg or by infusion at 0.1-0.3 mg/kg·h can effectively reduce cough reflexes caused by opioid induction,<sup>10</sup> prevent intraoperative hemodynamic fluctuations,<sup>11</sup> and reduce the need for intraoperative propofol and opioid medications.<sup>12 13</sup> However, it remains unclear whether subanesthetic doses of esketamine in general anaesthesia affect patient emergence and the incidence of postoperative delirium and agitation.<sup>14 15</sup>

This study retrospectively analyzes the effect of subanesthetic doses of esketamine used for intubation of general anaesthesia on recovery quality, postoperative pain and

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

88

89

90

91

adverse events in patients undergoing abdominal surgery. The objective is to provide clinical evidence regarding the effect of esketamine on recovery quality for abdominal surgery patients. Propensity score matching (PSM) was used to adjust pairs of patients with and without esketamine for potential confounders.

92

93

**Methods**

94

**Study design and patient population**

95

96

97

98

99

100

This retrospective, single-centre study was conducted at the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China). It was registered in the Chinese Clinical Trial Registry ([www.chictr.org.cn](http://www.chictr.org.cn), ChiCTR2300072154, 05/06/2023). The medical records used in this study were obtained from the medical database of the First Affiliated Hospital, Zhejiang University School of Medicine.

101

102

103

104

105

106

107

108

109

From December 20, 2022 to April 30, 2023, patients who had abdominal surgery under general anaesthesia with tracheal intubation were included in the study. Inclusion criteria included an American Society of Anesthesiologists (ASA) physical status of I to III, concurrent routine induction (sufentanil) with or without a subanesthetic dose of esketamine for general anaesthesia. Exclusion criteria were age <18 years or > 80 years, hepatic or renal dysfunction, severe pulmonary disease, severe cardiac dysfunction (New York Heart Association [NYHA] Classification 3-4), central nervous system disorders, psychiatric disorders, severe preoperative anemia, intraoperative bleeding  $\geq$  500 ml or severe intraoperative haemodynamic fluctuations

with markedly unstable vital signs caused by massive bleeding, duration of surgery > 240 min, postoperative intensive care unit (ICU) admission, and patients not transferred to the PACU after surgery.

### Anesthetic procedure

All patients underwent preoperative fasting. On admission to the operating room, patients were monitored with electrocardiogram (ECG), non-invasive upper arm blood pressure, pulse oxygen saturation ( $\text{SpO}_2$ ), respiratory rate, partial pressure of end-tidal carbon dioxide ( $\text{PetCO}_2$ ), body temperature, and bispectral index (BIS). Invasive continuous arterial pressure monitoring and central venous pressure monitoring were performed as needed.

Patients in the control group received with midazolam (0.04 mg/kg), propofol (1.0-2.0 mg/kg), rocuronium (0.6 mg/kg), and sufentanil (0.3-0.5  $\mu\text{g/kg}$ ). The esketamine group receives subanesthetic doses of esketamine (0.2 mg/kg) in addition to the above induction agents. During surgery, 0.8-1.5 minimum alveolar concentration (MAC) sevoflurane, 4-6 mg/kg·h propofol, and 0.1-0.3  $\mu\text{g/kg}\cdot\text{min}$  remifentanyl were maintained. After surgery, 5 mg tropisetron and 50 mg ketorolac were administered intravenously. Postoperative analgesia was achieved with 0.375% ropivacaine for nerve block (transversus abdominis plane block, TAP) or local wound infiltration anaesthesia.

Patients were transferred to the PACU after surgery, and endotracheal tubes were removed as soon as certain criteria were met (patients were awake,  $\text{RR} > 10$  breaths

per minute and tidal volume > 5 ml/kg). Inadequate muscle strength was treated with 0.04 mg/kg neostigmine and 0.02 mg/kg atropine intravenously. Supplemental oxygen at a rate of 2L/min was administered via nasal catheter after extubation. Pain was assessed using the Numeric Rating Scale (NRS) immediately, 15 minutes and 30 minutes after extubation. Hydromorphone (0.01mg/kg) was administered for pain relief if the NRS score exceeded 4 points. A jaw thrust or positive pressure ventilation with a face mask was used to treat respiratory depression. For dysphoria or delirium, propofol 0.5 mg/kg was used for sedation. If hypertension is diagnosed, intravenous amlodipine 5 mg is recommended. If hypotension occurs, ephedrine 6 mg should be administered. If shivering occurs, intravenous tramadol 50 mg is recommended. Discharge from the PACU was assessed using the modified Aldrete score, with a score of  $\geq 9$  indicating readiness for discharge.<sup>16 17</sup>

**Data collection**

Demographic and perioperative data were collected from the clinical information system (Seenew, Hangzhou, China) and institutional electronic Anaesthesia Data Sysytem (Medical System, Suzhou, China), including: 1) preoperative data: gender, age, body mass index (BMI), medical history, and ASA classification; 2) intraoperative data: type of surgery, surgery duration, anaesthesia duration, intraoperative blood loss, and use of the patient-controlled analgesia (PCA); 3) PACU data: heart rate, blood pressure, oxygen saturation, extubation time, PACU observation time, the total PACU time, postoperative pain (NRS score), analgesic use,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

incidence of hypertension, hypotension, and medication use. Additionally, the modified Aldrete score, respiratory depression, delirium and agitation, nausea/vomiting, shivering, and other PACU adverse events (e.g., reintubation) were recorded.

### **Primary outcome**

The primary outcome was extubation time (T1), defined as the time from discontinuation of anaesthesia to extubation (minutes).

### **Secondary outcome**

Secondary outcomes included postoperative pain immediately after extubation, at 15 minutes, and at 30 minutes, and analgesic use. The modified Aldrete score at PACU discharge and the incidence of PACU adverse events including respiratory depression, hypertension, hypotension, delirium, agitation, nausea/vomiting, shivering, reintubation, and use of symptomatic treatment were recorded.

Respiratory depression was defined as respiratory rate falling below 8 breaths per minute or  $\text{SpO}_2 < 90\%$  for more than 1 minute.<sup>18 19</sup> In addition, the comparison of PACU observation time (T2), defined as the time from extubation to PACU discharge, total PACU time (T3), defined as the interval from PACU admission to discharge, and PACU discharge delay rate, defined as the percentage of patients with a PACU time greater than 120 minutes, were analyzed.

**Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Propensity score matching**

Propensity score matching (PSM) analysis was performed using R Project for Statistical Computing (Version 4.2.3, Lucent Technologies, Reston, USA) and the matchIt package to reduce differences between the two groups based on the esketamine administration to minimize confounding factors. It is generally accepted that a standardised mean difference (SMD) of less than 0.1 for all variables indicates a good fit<sup>20</sup>. For binary variables, the SMD is the difference in event rates between the treatment and control groups divided by the pooled standard deviation, where the pooled p is the weighted average of the event rates in both groups. For multi-category variables, the variable is split into several binary dummy variables and the SMD is calculated separately for each dummy variable, taking the maximum absolute value. Nearest-neighbor matching method was used in a 1:1 ratio, with a caliper value of 0.05. Matching variables were selected based on prior literature where there was evidence of being potential confounders<sup>21</sup> and included age, gender, BMI, chronic disease, ASA physical status classification, surgical category, surgery duration, anaesthesia duration, intraoperative blood loss, and PCA use. The absolute standardised mean differences (SMD) are less than 0.1 for all variables. Multiple linear regression analysis was used to complete the matching process.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

198

## 199 **Statistical analysis**

200 Sample size was calculated using PASS statistical software (NCSS LLC, Kaysville,  
201 USA). This was a retrospective case-control study. In the preliminary study, we  
202 included 20 patients in each group, and the mean extubation times for the two groups  
203 were  $19.00 \pm 11.52$  min and  $22.15 \pm 14.42$  min, respectively. A two-tailed test with  $\alpha$  set  
204 at 0.05, 90% power and a sample size of 1:1 indicated that a minimum sample size of  
205 361 participants per group was required. As PSM will be used for case selection, we  
206 included a larger sample size to ensure that the final number after PSM met the  
207 required threshold.

208 All quantitative data were assessed for normality using the Shapiro-Wilk test.  
209 Normally distributed continuous data were presented as mean (standard deviation),  
210 and differences between groups were analyzed using t-tests or analysis of variance  
211 (ANOVA). Skewed data were presented as median (25<sup>th</sup>-75<sup>th</sup> percentile) and were  
212 analyzed using the nonparametric Mann-Whitney U test. Categorical data were  
213 analyzed using the chi-squared test or Fisher's exact test. Ordinal data were analyzed  
214 using the Wilcoxon rank-sum test. All statistical analyses were performed with the  
215 SPSS software 22.0 (IBM corp., NY, USA). Statistical significance was defined as a P  
216 value  $< 0.05$ .

217

## 218 **Results**

### 219 **Demographic and patient characteristics**

A total of 2,177 patients with ASA physical status of I to III under sufentanil anaesthesia underwent abdominal surgery, including hepatobiliary, gastrointestinal, and colorectal surgery, at the First Affiliated Hospital, Zhejiang University School of Medicine. Based on the inclusion and exclusion criteria, a final of 1,718 patients were enrolled, with 633 patients in the esketamine group and 1,085 patients in the control group. PSM successfully matched 598 patients in each group, achieving the required sample size (Figure 1). The use of PSM ensured that the baseline characteristics were similar between the two groups (Figure 2). The distributions of the propensity scores and the SMD of the covariates were well balanced after PSM adjustment (Figure 3).

Patient characteristics in the esketamine group and control groups before and after PSM are shown in Table 1. After PSM, there were no significant differences ( $P > 0.05$ ) in the patient characteristics in gender, age, BMI, medical history, ASA classification, type of surgery, surgery duration, anaesthesia duration, intraoperative blood loss, and use of the PCA between the two groups.

**Primary outcome**

The results showed that the extubation time (T1) in the esketamine group was 20 (11, 32) minutes, while the T1 in the control group was 23 (13, 37) minutes ( $P = 0.001$ ), indicating that patients induced with subanesthetic doses of esketamine had faster recovery in the PACU (Table 2). Multiple linear regression suggests that ketamine is an independent protective factor for extubation time (Supplementary Table 1).

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

## Secondary outcome

The number of patients with severe postoperative pain immediately after extubation was significantly higher in the control group (12, 2.01%) than that in the esketamine groups (2, 0.33%) ( $p = 0.007$ ). In addition, the number of patients requiring additional hydromorphone for postoperative pain during PACU treatment was significantly higher in the control group (94, 15.72%) than in the esketamine group (70, 11.71%) ( $p = 0.044$ ). However, there were no statistically significant differences in the number of patients with postoperative pain between the two groups at 15 and 30 minutes after extubation, as shown in Table 3.

During the PACU period, the number of patients with respiratory depression in the control group was 32 (5.35%), significantly higher than the 16 (2.68%) cases in the esketamine group ( $p=0.027$ ). The esketamine group had a significantly higher rate of hypertension than the control group (9.53% vs. 6.35%,  $p=0.042$ ). There were no significant differences in hypotension, delirium and agitation, nausea and vomiting, or shivering between the two groups. There were no emergencies requiring reintubation in either group. There were also no statistically significant differences in the modified Aldrete scores between the two groups when patients left the PACU (Table 4).

In addition, the total PACU time (T3) was also shorter in the esketamine group (62.00 vs. 66.00,  $p=0.015$ ). However, there was no significant difference in the PACU observation time (T2) between the two groups, with median times of 38 minutes in the control group and 37 minutes in the esketamine group ( $p = 0.738$ ). The number of

patients with delayed discharge from the PACU was 30 (5.02%) in the esketamine group and 38 (6.35%) in the control group, respectively ( $p = 0.318$ ) (Table 2).

**Discussion**

The results of the current study indicate that the use of subanesthetic doses of esketamine can effectively reduce the postoperative extubation time in the PACU for patients undergoing abdominal surgery. In addition, esketamine was found to reduce postoperative pain without increasing post-extubation side effects.

Previously, it was thought that the combining different mechanisms, such as esketamine with midazolam, propofol, or sevoflurane, could deepen the level of anaesthesia and influence patient recovery.<sup>22 23</sup> However, recent studies have shown that esketamine not only increases the depth of anaesthesia but also accelerates recovery from anaesthesia.<sup>24</sup> Animal studies have shown that ketamine, the parent compound of esketamine, can shorten the peak activation time of the glutamatergic neurons, particularly those in the paraventricular thalamus (PVT), thereby reducing extubation time. Clinical studies have also shown that patients who received subanesthetic doses of esketamine intraoperatively had faster and better recovery of postoperative respiratory rate and tidal volume.<sup>25</sup> The current study supports these findings and suggests that the use of subanesthetic doses of esketamine may accelerate patient recovery.

This research shows that subanesthetic doses of esketamine are effective in relieving immediate post-extubation pain after extubation. Animal studies have

suggested that the combining of NMDA receptor antagonists with opioids may result in synergistic or additive analgesic effects.<sup>26</sup> Numerous clinical studies have supported this concept by demonstrating that administration of 0.15-0.5 mg/kg of esketamine reduces intraoperative opioid consumption and improves postoperative pain management.<sup>12 13 27 28</sup> Consistent with these findings, the present study shows similar results. The subgroup that receiving subanesthetic doses of esketamine reported significantly lower pain levels immediately after extubation. While there was no significant difference in pain scores between the two groups at 15 and 30 minutes post-extubation, the PACU observation period showed a significant reduction in the number of patients in the esketamine group requiring additional analgesics for postoperative pain relief compared to the control group, indicating the beneficial effect of subanesthetic doses of esketamine on overall postoperative pain relief. The major metabolite of esketamine is S-norketamine, which has approximately one-third the analgesic potency of esketamine and a longer elimination half-life. This may explain the prolonged analgesic effect of esketamine in the PACU.<sup>25</sup>

The results of this study indicate that the incidence of respiratory depression was significantly lower in the esketamine group than that in the control group. Respiratory depression is a common adverse event in the PACU, with an incidence rate of approximately 5%,<sup>18</sup> which is similar to the incidence observed in the control group of this study. Causes of respiratory depression during the anesthetic recovery period include the use of opioids, residual effects of muscle relaxants, and the incomplete recovery of the respiratory system after surgery. It's worth noting that approximately

20% of cases of respiratory depression are associated with the use of opioid medications.<sup>29</sup> Elevated carbon dioxide (CO<sub>2</sub>) levels can stimulate central chemoreceptors, leading to an increase in respiratory drive. However, the use of opioid medications attenuates this response.<sup>30</sup> Both animal and clinical studies have shown that ketamine can enhance CO<sub>2</sub> sensitivity and provide moderate protection against respiratory depression and bronchoconstriction.<sup>31 32</sup> Research by Jonkman *et al.* also suggests that low-dose esketamine may counteract the respiratory depressant effects of opioid drugs.<sup>33</sup> This suggests that the use of subanesthetic doses of esketamine to induce anaesthesia may not only reduce opioid consumption but also stabilize respiration, thereby reducing the likelihood of fatal events.

The most common adverse events associated with esketamine primarily are psychological symptoms such as delirium, agitation, nightmares, and dissociative phenomena, which often follow a dose-dependent pattern.<sup>34 35</sup> Bornemann-Cimenti H *et al.* have confirmed that subanesthetic doses can reduce the incidence of psychological symptoms associated with esketamine.<sup>36</sup> Our study supports this view and shows that subanesthetic doses of esketamine do not increase the incidence of delirium or agitation. In addition, there is no effect on the incidence of nausea and vomiting. The sympathomimetic effects of esketamine, which manifest as increased blood pressure and heart rate.<sup>11 37</sup> The incidence of hypertension was higher in the esketamine group than in the control group. This may be due to the increased blood pressure induced by esketamine.

The primary goal of the PACU is to improve turnover efficiency between surgical

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

procedures and to increase patient satisfaction. Factors such as delirium, agitation, and postoperative pain can prolong the PACU stay.<sup>38</sup> However, the current study shows that the use of a subanesthetic dose of esketamine doesn't increase the incidence of these complications. Furthermore, the total PACU time for the esketamine group is shorter than that of the control group, suggesting that the use of esketamine may improve the efficiency of the PACU.

There are several limitations to this study. First, it is a single-centre, retrospective study, which may limit the generalisability of the findings. Although the two groups were matched on several demographic factors, there remains the potential for residual confounding due to unmeasured variables affecting the propensity score analysis. In addition, the lack of sensitivity analysis may affect the robustness of the results. Second, the dose of esketamine is subanesthetic, and the study did not investigate potential problems associated with other doses. Finally, this study focuses exclusively on patients undergoing abdominal surgery and does not include other types of surgery. Therefore, further research should include large, multicentre, prospective studies to fully address these limitations.

## Conclusions

Subanesthetic doses of esketamine have been shown to be effective in reducing the extubation time in patients undergoing abdominal surgery under general endotracheal anaesthesia, without compromising the overall quality of recovery. In addition, the use of subanesthetic doses of esketamine has the potential to reduce the incidence of

severe postoperative pain, thereby reducing the need for analgesia in the PACU. This approach also helps to reduce the incidence of respiratory depression, resulting in a shorter overall PACU time, and ultimately contributing to the overall recovery process for patients.

**Contributions** DW, XF and YJ contributed to the study design. MW, KC, XW, YX, YW, MQ and ZL contributed to data acquisition. DW contributed to data analysis and drafting of the paper. XF and YJ contributed to manuscript revision. YJ contributed to final approval of the version. All authors read and approved the final version. YJ is the guarantor.

**Funding** This work was supported by National Natural Science Foundation of China (82372159 and 82230074).

**Conflicting interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** The study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (IIT20230403A), and registered in the Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR2300072154).

**Data availability statement** Data will be made available on request. Further inquiries can be directed to the corresponding authors.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

---

## References

1. Ng-Kamstra JS, Nepogodiev D, Lawani I, et al. Perioperative mortality as a meaningful indicator: Challenges and solutions for measurement, interpretation, and health system improvement. *Anaesth Crit Care Pain Med* 2020;39:673-81.
2. Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. *N Engl J Med* 2010;363:2638-50.
3. Bainbridge D, Martin J, Arango M, et al. Perioperative and anaesthetic-related mortality in developed and developing countries: a systematic review and meta-analysis. *Lancet* 2012;380:1075-81.
4. Shuying L, Ping L, Juan N, et al. Different interventions in preventing opioid-induced cough: a meta-analysis. *J Clin Anesth* 2016;34:440-7.
5. Hirsch J, DePalma G, Tsai TT, et al. Impact of intraoperative hypotension and blood pressure fluctuations on early postoperative delirium after non-cardiac surgery. *Br J Anaesth* 2015;115:418-26.
6. Popping DM, Zahn PK, Van Aken HK, et al. Effectiveness and safety of postoperative pain management: a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision): a database analysis of prospectively raised data. *Br J Anaesth* 2008;101:832-40.
7. Niu X, Zheng S, Li S, et al. Role of Different Doses of Ketamine in Postoperative Neurocognitive Function in Aged Mice Undergoing Partial Hepatectomy by Regulating the Bmal1/NMDA/NF-Kappab Axis. *Eur Surg Res*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Ensignment Supérieur (ABES)

2022;63:182-95.

8. Wang J, Huang J, Yang S, et al. Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study. *Drug Des Devel Ther* 2019;13:4135-44.

9. Xu Y, He L, Liu S, et al. Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. *PLoS One* 2023;18:e0286590.

10. Guler G, Aksu R, Bicer C, et al. Comparison of the effects of ketamine or lidocaine on fentanyl-induced cough in patients undergoing surgery: A prospective, double-blind, randomized, placebo-controlled study. *Curr Ther Res Clin Exp* 2010;71:289-97.

11. Li J, Wang Z, Wang A, et al. Clinical effects of low-dose esketamine for anaesthesia induction in the elderly: A randomized controlled trial. *J Clin Pharm Ther* 2022;47:759-66.

12. Wang P, Song M, Wang X, et al. Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial. *Br J Clin Pharmacol* 2023;89:2542-51.

13. Min M, Du C, Chen X, et al. Effect of subanesthetic dose of esketamine on postoperative rehabilitation in elderly patients undergoing hip arthroplasty. *J Orthop Surg Res* 2023;18:268.

14. Zhang C, He J, Shi Q, et al. Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial. *BMC Anesthesiol* 2022;22:138.
15. Chen S, Yang JJ, Zhang Y, et al. Risk of esketamine anesthesia on the emergence delirium in preschool children after minor surgery: a prospective observational clinical study. *Eur Arch Psychiatry Clin Neurosci* 2023;274:767-75.
16. Hawker RJ, McKillop A, Jacobs S. Postanesthesia Scoring Methods: An Integrative Review of the Literature. *J Perianesth Nurs* 2017;32:557-72.
17. Abdullah HR, Chung F. Postoperative issues: discharge criteria. *Anesthesiol Clin* 2014;32:487-93.
18. Laporta ML, Sprung J, Weingarten TN. Respiratory depression in the post-anesthesia care unit: Mayo Clinic experience. *Bosn J Basic Med Sci* 2021;21:221-28.
19. Eberl S, Koers L, van Hooft J, et al. The effectiveness of a low-dose esketamine versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatography: A randomised controlled multicentre trial. *Eur J Anaesthesiol* 2020;37:394-401.
20. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;28:3083-107.
21. Hasselager RP, Hallas J, Gogenur I. Inhalation or total intravenous anaesthesia and recurrence after colorectal cancer surgery: a propensity score matched

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

440 Danish registry-based study. *Br J Anaesth* 2021;126:921-30.

441 22. Rosow CE. Anesthetic drug interaction: an overview. *J Clin Anesth*  
442 1997;9:27S-32S.

443 23. Hendrickx JF, Eger EI, 2nd, Sonner JM, et al. Is synergy the rule? A review of  
444 anesthetic interactions producing hypnosis and immobility. *Anesth Analg*  
445 2008;107:494-506.

446 24. Duan WY, Peng K, Qin HM, et al. Esketamine accelerates emergence from  
447 isoflurane general anaesthesia by activating the paraventricular thalamus  
448 glutamatergic neurones in mice. *Br J Anaesth* 2024;132:334-42.

449 25. Yuan J, Chen S, Xie Y, et al. Intraoperative Intravenous Infusion of Esmketamine  
450 Has Opioid-Sparing Effect and Improves the Quality of Recovery in Patients  
451 Undergoing Thoracic Surgery: A Randomized, Double-Blind,  
452 Placebo-Controlled Clinical Trial. *Pain Physician* 2022;25:E1389-E97.

453 26. Gupta A, Devi LA, Gomes I. Potentiation of mu-opioid receptor-mediated  
454 signaling by ketamine. *J Neurochem* 2011;119:294-302.

455 27. Nielsen RV, Fomsgaard JS, Siegel H, et al. Intraoperative ketamine reduces  
456 immediate postoperative opioid consumption after spinal fusion surgery in  
457 chronic pain patients with opioid dependency: a randomized, blinded trial.  
458 *Pain* 2017;158:463-70.

459 28. Lei Y, Liu H, Xia F, et al. Effects of Esketamine on Acute and Chronic Pain After  
460 Thoracoscopy Pulmonary Surgery Under General Anesthesia: A  
461 Multicenter-Prospective, Randomized, Double-Blind, and Controlled Trial.

- 462 *Front Med (Lausanne)* 2021;8:693594.
- 463 29. Weingarten TN, Sprung J. Review of Postoperative Respiratory Depression: From  
464 Recovery Room to General Care Unit. *Anesthesiology* 2022;137:735-41.
- 465 30. Ayad S, Khanna AK, Iqbal SU, et al. Characterisation and monitoring of  
466 postoperative respiratory depression: current approaches and future  
467 considerations. *Br J Anaesth* 2019;123:378-91.
- 468 31. De Oliveira GS, Jr., Fitzgerald PC, Hansen N, et al. The effect of ketamine on  
469 hypoventilation during deep sedation with midazolam and propofol: a  
470 randomised, double-blind, placebo-controlled trial. *Eur J Anaesthesiol*  
471 2014;31:654-62.
- 472 32. Eikermann M, Grosse-Sundrup M, Zaremba S, et al. Ketamine activates breathing  
473 and abolishes the coupling between loss of consciousness and upper airway  
474 dilator muscle dysfunction. *Anesthesiology* 2012;116:35-46.
- 475 33. Jonkman K, van Rijnsoever E, Olofsen E, et al. Esketamine counters  
476 opioid-induced respiratory depression. *Br J Anaesth* 2018;120:1117-27.
- 477 34. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite  
478 Pharmacology: Insights into Therapeutic Mechanisms. *Pharmacol Rev*  
479 2018;70:621-60.
- 480 35. Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. *J*  
481 *Psychopharmacol* 2021;35:109-23.
- 482 36. Bornemann-Cimenti H, Wejbora M, Michaeli K, et al. The effects of  
483 minimal-dose versus low-dose S-ketamine on opioid consumption,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

484           hyperalgesia, and postoperative delirium: a triple-blinded, randomized, active-  
485           and placebo-controlled clinical trial. *Minerva Anesthesiol* 2016;82:1069-76.

486   37. Zhou N, Liang X, Gong J, et al. S-ketamine used during anesthesia induction  
487           increases the perfusion index and mean arterial pressure after induction: A  
488           randomized, double-blind, placebo-controlled trial. *Eur J Pharm Sci*  
489           2022;179:106312.

490   38. Munk L, Andersen G, Moller AM. Post-anaesthetic emergence delirium in adults:  
491           incidence, predictors and consequences. *Acta Anaesthesiol Scand*  
492           2016;60:1059-66.

---

## Figure legends

**Figure 1.** Flowchart of patient selection.

**Figure 2.** Standardized mean differences of covariates after PSM.

**Figure 3.** Distributions of propensity scores after PSM.

For peer review only

**Table 1.** Comparison between the esketamine and control groups before and after propensity-score matching

	Before PSM				After PSM			
	Total (n=1718)	Control Group (n=1085)	Esketamine Group (n=633)	P	Total (n=1196)	Control Group (n=598)	Esketamine Group (n=598)	P
Age (year), median (IQR)	58.00 (45.00, 66.00)	57.00 (43.00, 66.00)	58.00 (49.00, 66.00)	0.075	58.00 (47.00, 66.00)	58.00 (44.00, 67.00)	58.00 (48.00, 65.00)	0.477
Gender, n (%)								0.954
Male	777 (45.23)	495 (45.62)	282 (44.55)		533 (44.57)	266 (44.48)	267 (44.65)	
Female	941 (54.77)	590 (54.38)	351 (55.45)		663 (55.43)	332 (55.52)	331 (55.35)	
BMI, median (IQR)	23.41 (21.23, 25.39)	23.39 (21.23, 25.40)	23.44 (21.23, 25.34)	0.858	23.40 (21.19, 25.39)	23.39 (21.10, 25.40)	23.44 (21.24, 25.35)	0.862
Chronic disease								
Hypertension, n (%)				0.768				0.880
No	1412 (82.19)	894 (82.40)	518 (81.83)		982 (82.11)	492 (82.27)	490 (81.94)	
Yes	306 (17.81)	191 (17.60)	115 (18.17)		214 (17.89)	106 (17.73)	108 (18.06)	
Diabetes, n (%)				0.375				0.212
No	1618 (94.18)	1026 (94.56)	592 (93.52)		1128 (94.31)	569 (95.15)	559 (93.48)	
Yes	100 (5.82)	59 (5.44)	41 (6.48)		68 (5.69)	29 (4.85)	39 (6.52)	
Coronary heart disease, n (%)				0.190				0.176
No	1690 (98.37)	1064 (98.06)	626 (98.89)		1176 (98.33)	585 (97.83)	591 (98.83)	
Yes	28 (1.63)	21 (1.94)	7 (1.11)		20 (1.67)	13 (2.17)	7 (1.17)	
COPD, n (%)				0.151				0.615
No	1699 (98.89)	1076 (99.17)	623 (98.42)		1180 (98.66)	599 (98.83)	589 (98.49)	
Yes	19 (1.11)	9 (0.83)	10 (1.58)		16 (1.34)	7 (1.17)	9 (1.51)	
ASA physical status, n (%)								0.160
I	143 (8.32)	100 (9.22)	43 (6.79)		97 (8.11)	51 (9.53)	40 (6.69)	

II	1441 (83.88)	901 (83.04)	540 (85.31)		1016 (84.95)	503 (84.11)	513 (85.79)	
III	134 (7.8)	84 (7.74)	50 (7.90)		83 (6.94)	38 (6.35)	45 (7.53)	
Surgery type, n (%)				<0.001				0.515
Hepatobiliary surgery	919 (53.49)	622 (57.33)	297 (46.92)		597 (49.92)	225 (50.50)	295 (49.33)	
Gastrointestinal surgery	460 (26.78)	279 (25.71)	181 (28.59)		333 (27.84)	88 (26.42)	175 (29.26)	
Colorectal surgery	339 (19.73)	184 (16.96)	155 (24.49)		266 (22.24)	88 (23.08)	128 (21.40)	
Surgery duration (min) , median (IQR)	60.00 (38.00, 121.00)	55.00 (37.00, 112.00)	68.00 (41.00, 135.00)	<0.001	62.00 (39.00, 127.00)	58.25 (38.25, 77.75)	63.00 (40.00, 126.75)	0.757
Anaesthesia duration (min), median (IQR)	82.00 (58.00, 155.00)	79.00 (56.00, 147.00)	90.00 (60.00, 170.00)	<0.001	86.00 (58.00, 159.25)	75.00 (57.00, 111.00)	86.00 (59.00, 157.75)	0.858
Intraoperative blood loss (ml) , median (IQR)	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	0.004	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	10.00 (10.00, 50.00)	0.580
PCA, n (%)				0.102				0.195
Yes	1197 (69.67)	771 (71.06)	426 (67.30)		807 (67.47)	393 (65.72)	414 (69.23)	
No	521 (30.33)	314 (28.94)	207 (32.70)		389 (32.53)	205 (34.28)	184 (30.77)	

ASA: American Society of Anesthesiologists; BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCA: Patient controlled analgesia; PSM: propensity score matching; SMD: standardized mean differences

**Table 2.** Recovery time after surgery.

	Control Group	Esketamine Group	<i>P</i> value
	(n=598)	(n=598)	
T1 (min), median (IQR)	23.00 (13.00, 37.00)	20.00 (11.00, 32.00)	0.001
T2 (min), median (IQR)	38.00 (31.00, 50.00)	37.00 (31.00, 50.00)	0.738
T3 (min), median (IQR)	66.00 (51.00, 85.00)	62.00 (48.00, 82.00)	0.015
Delayed PACU discharge, n (%)	38 (6.35)	30 (5.02)	0.318

PACU: post-anesthesia care unit; T1: extubation time; T2: PACU observation time; T3: The total PACU time.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

**Table 3.** Postoperative pain scores and analgesic requirements.

	Control Group (n=598)	Esketamine Group (n=598)	<i>P</i> value
Postoperative pain immediately after extubation			0.007
NRS: 1-3	586 (97.99)	596 (99.67)	
NRS: $\geq 4$	12 (2.01)	2 (0.33)	
Postoperative pain, 15 minutes after extubation			0.235
NRS: 1-3	524 (87.63)	537 (89.80)	
NRS: $\geq 4$	74 (12.37)	61 (10.20)	
Postoperative pain, 30 minutes after extubation			0.365
NRS: $\geq 4$	12 (2.01)	8 (1.34)	
Use of analgesic drugs	94 (15.72)	70 (11.71)	0.044

Data are presented as n (%).


NRS: Numeric Rating Scale

**Table 4. Postoperative adverse events and the modified Aldrete score**

	Control Group (n=598)	Esketamine Group (n=598)	<i>P</i> value
Respiratory depression	32 (5.35)	16 (2.68)	0.027
Hypotension	15 (2.51)	14 (2.34)	0.851
Hypertension	38 (6.35)	57 (9.53)	0.042
Delirium and agitation	88 (14.72)	91 (15.22)	0.808
Nausea and vomiting	24 (4.01)	27 (4.52)	0.668
Shivering	14 (2.3)	17 (2.8)	0.584
Reintubation	0	0	-
The modified Aldrete score			0.502
9 points	40 (6.69)	46 (7.69)	
10 points	558 (93.31)	552 (92.31)	


Data are presented as n (%).

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).




214x169mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



Treatment ■ Control ■ Esketamine

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38



For peer review only - <http://bmjopen.bmj.com/submit/about/guidelines.xhtml>

BMJ Open: first published as 10.1136/bmjopen-2024-029444 on 30 May 2025. Downloaded from <http://bmjopen.bmj.com/> on June 8, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).  
All rights reserved. No reuse allowed without permission. See <http://bmjopen.bmj.com/submit/about/guidelines.xhtml> for uses related to text and data mining, AI training, and similar technologies.

Supplementary data

Supplement Table 1. Results of multiple linear regression analysis

Variables	b	S.E	t	$\beta$ (95%CI)	P	m_b	m_S.E	m	a $\beta$ (95%CI)	aP
Age	0.27	0.04	7.09	0.27 (0.20 ~ 0.35)	<.001	0.20	0.04	5.23	0.20 (0.12 ~ 0.27)	<.001
Gender										
Male				0.00 (Reference)						
Female	1.38	1.12	1.23	1.38 (-0.82 ~ 3.58)	0.218					
BMI	-0.89	0.17	-5.34	-0.89 (-1.21 ~ -0.56)	<.001	-0.60	0.16	-3.8	-0.60 (-0.91 ~ -0.30)	<.001
Chronic disease										
Hypertension										
No				0.00 (Reference)						
Yes	0.20	1.46	0.14	0.20 (-2.65 ~ 3.06)	0.888					
Diabetes										
No				0.00 (Reference)						
Yes	-1.78	2.41	-0.74	-1.78 (-6.51 ~ 2.94)	0.459					
Coronary heart disease										
No				0.00 (Reference)						
Yes	3.28	4.35	0.75	3.28 (-5.25 ~ 11.81)	0.451					
COPD										
No				0.00 (Reference)					0.00 (Reference)	
Yes	11.59	4.85	2.39	11.59 (2.10 ~ 21.09)	0.017	5.42	4.48	1.21	5.42 (-3.36 ~ 14.20)	0.226
ASA physical status										
I				0.00 (Reference)						
II	3.82	2.05	1.86	3.82 (-0.20 ~ 7.83)	0.062					
III	3.34	2.88	1.16	3.34 (-2.31 ~ 8.99)	0.246					
Surgery type										
Hepatobiliary surgery				0.00 (Reference)					0.00 (Reference)	
Gastrointestinal surgery	-3.97	1.29	-3.08	-3.97 (-6.50 ~ -1.44)	0.002	-3.70	1.23	-3.00	-3.70 (-6.12 ~ -1.28)	0.003

Colorectal surgery	7.89	1.39	5.68	7.89 (5.17 ~ 10.61)	<.001	1.20	1.60	0.71	1.20 (-1.92 ~ 4.33)	0.451
Surgery duration (min)	0.09	0.01	9.58	0.09 (0.07 ~ 0.11)	<.001	0.05	0.07	0.81	0.05 (-0.08 ~ 0.18)	0.417
Anesthesia duration (min)	0.09	0.01	9.80	0.09 (0.07 ~ 0.10)	<.001	-0.05	0.06	-0.71	-0.05 (-0.17 ~ 0.07)	0.442
Intraoperative blood loss (ml)	0.10	0.01	10.50	0.10 (0.08 ~ 0.12)	<.001	0.06	0.01	5.37	0.06 (0.04 ~ 0.08)	<.001
Esketamine										
No				0.00 (Reference)					0.00 (Reference)	
Yes	-3.35	1.11	-3.01	-3.35 (-5.53 ~ -1.17)	0.003	-2.83	1.02	-2.71	-2.83 (-4.84 ~ -0.83)	0.006
PCA										
No				0.00 (Reference)					0.00 (Reference)	
Yes	12.55	1.13	11.06	12.55 (10.32 ~ 14.77)	<.001	6.04	1.67	3.62	6.04 (2.77 ~ 9.31)	<.001

ASA: American Society of Anesthesiologists; BMI: body mass index; COPD: chronic obstructive pulmonary disease; PCA: Patient controlled analgesia; PSM: propensity score matching